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SUMMARY 
Autism spectrum disorders (ASD) are a group of genetic disorders often overlapping with 
other neurological conditions. We previously described abnormalities in the branched 
chain amino acid (BCAA) catabolic pathway as a cause of ASD. Here we show that the 
solute carrier transporter 7a5 (SLC7A5), a large neutral amino acid transporter localized 
at the blood brain barrier (BBB), has an essential role in maintaining normal levels of 
brain BCAAs. In mice, deletion of Slc7a5 from the endothelial cells of the BBB leads to 
atypical brain amino acid profile, abnormal mRNA translation and severe neurological 
abnormalities. Furthermore, we identified several patients with autistic traits and motor 
delay carrying deleterious homozygous mutations in the SLC7A5 gene. Finally, we 
demonstrate that BCAA intracerebroventricular administration ameliorates abnormal 
behaviors in adult mutant mice. Our data elucidate a neurological syndrome defined by 
SLC7A5 mutations and support an essential role for the BCAA in human brain function. 
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INTRODUCTION 
Autism spectrum disorders (ASD) is a group of syndromes of heterogeneous etiologies 
characterized by impairment in social interactions, verbal communication and repetitive 
behaviors. A number of twin and family studies have shown that genetics play a 
significant role in the development of ASD (Bailey et al., 1995; Folstein and Rutter, 1977). 
However, the genetic architecture of ASD is very complex and mutations in a single gene 
rarely account for a significant proportion of ASD patients. Despite their genetic 
heterogeneity, ASD may be less diverse functionally. Indeed, in many instances the great 
number of genes implicated in neurological disorders converges on a smaller number of 
biological pathways (De Rubeis et al., 2014). 
We recently identified mutations in the gene branched chain keto-acid 
dehydrogenase kinase (BCKDK) in several patients with ASD, ID and epilepsy (Novarino 
et al., 2012). BCKDK is the enzyme responsible for the rate-limiting step in the catabolic 
pathway of the Branched Chain Amino Acids (BCAAs), a group of essential amino acids 
comprising valine, leucine and isoleucine. The most direct consequence of BCKDK 
mutations is a hyper-catabolism of the BCAAs, resulting in abnormally low levels of 
serum and brain BCAAs (Novarino et al., 2012).    
The brain is dependent on a constant supply of BCAAs from the periphery. Should 
BCAAs be substantially important for the brain, factors facilitating BCAA uptake might be 
critical for the proper function of the central nervous system. The Large Neutral Amino 
Acid Transporter 1 (LAT1) is encoded by the SLC7A5 gene (Verrey, 2003). The 
transporter is localized at the blood brain barrier (BBB) and forms a heterodimer with the 
glycoprotein CD98, encoded by the SLC3A2 gene. 
Here we studied a mouse model in which Slc7a5 was deleted from the BBB and 
found that Slc7a5 is particularly important to set brain BCAA levels within a normal range. 
Mice with defective BCAA transport at the BBB show abnormal activation of the amino 
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acid response (AAR) pathway and a corresponding reduction in mRNA translation along 
with neuronal activity imbalance and behavioral problems. To probe whether SLC7A5 is 
essential also in humans, we performed genetic analysis of a cohort of neurological 
pediatric patients. We identified and functionally validated, mutations in SLC7A5 in 
several patients with ASD and motor coordination problems. Notably, neurological 
abnormalities can be treated in adult mice by 3-week long intracerebroventricular (i.c.v.) 
BCAA delivery. 
 
RESULTS 
SLC7A5 mediates BCAA flux at the BBB 
Earlier in vitro studies described the sodium independent LAT1 as a large neutral 
amino acid (LNAA) transporter, including the BCAAs (Mastroberardino et al., 1998). The 
light subunit of the carrier, encoded by SLC7A5, is sufficient to transport LNAAs 
(Napolitano et al., 2015). The contribution of SLC7A5 to brain LNAA/BCAA homeostasis 
in vivo, however, remains completely unknown.  
To understand the physiological role of Slc7a5 in vivo, we employed a conditional 
(floxed) Slc7a5 knock out mouse line (Slc7a5fl) (Sinclair et al., 2013). In wild type 
animals, Slc7a5 is considerably expressed in the plasma membrane of the endothelial 
cells of the BBB during development and in adulthood but it is mostly undetectable in 
other tissues (Figure 1A and Figure S1A-C). Thus, we crossed the Slc7a5fl mouse with 
the Tie2Cre mouse line, expressing the Cre recombinase starting from embryonic day (E) 
11.5 in the endothelial cells of blood vessels and BBB (Figure S1D) (Kisanuki et al., 
2001). As expected, endothelial cells of the BBB of Tie2Cre;Slc7a5fl/fl mice show complete 
lack of expression of Slc7a5 (Figure 1A).  
The exchange between blood and cerebrospinal fluid of a wide range of 
metabolically important molecules, including amino acids, is known to be constrained 
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already early during development, arising with the BBB formation. However, some 
studies reported that many amino acids, including the BCAAs, are transported into the 
developing brain at much higher rate than in adulthood (Braun et al., 1980; Lefauconnier 
and Trouve, 1983). Whether this reflects a greater metabolic demand of the developing 
brain or the immaturity of the BBB is unknown (Watson et al., 2006). Hence, we asked 
how removal of Slc7a5 from the BBB affects brain amino acid levels at different 
developmental stages.  
We found that E14.5 Tie2Cre;Slc7a5fl/fl mice don’t show major changes in brain 
LNAA and BCAA levels (Figure 1B), suggesting either that at E14.5 the BBB is still 
immature, with amino acids leaking into the brain, or that another transporter may 
regulate LNAA and BCAA fluxes across the BBB during early development. In contrast, 
after birth and in adult stages brain BCAA, especially leucine and isoleucine, levels are 
abnormally low in Tie2Cre;Slc7a5fl/fl animals (Figure 1C-D), indicating that Slc7a5 
expression is essential to regulate BCAA uptake by the brain. Surprisingly, the brain 
levels of several other LNAAs (e.g. tyrosine and tryptophan) in Slc7a5 mutants are 
comparable to the ranges observed in control (Tie2Cre;Slc7a5fl/+) animals, while a few 
other amino acids (e.g. histidine, serine and phenylalanine) show an elevated level in 
mutants compared to controls. In particular, brain histidine concentration is several fold 
higher in the Tie2Cre;Slc7a5fl/fl mice than in control animals (Figure 1B-D). This result 
supports the idea that SLC7A5 works as an antiporter and that histidine is the main 
counter amino acid (Figure S2) (Napolitano et al., 2015).   
Thus, in the absence of Slc7a5 expression at the BBB, the mammalian brain 
accumulates histidine while failing to gather normal amounts of BCAAs. Importantly, 
neither the serum amino acid profile nor the level of brain neurotransmitters are affected 
in the Tie2Cre;Slc7a5fl/fl animals (Figure S2C and Table S1). While this last result 
contradicts previous hypotheses (del Amo et al., 2008), it is in agreement with our in vitro 
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experiments showing that SLC7A5 does not facilitate the movement of neurotransmitters 
(Figure S2A-B). 
 
Deletion of Slc7a5 from the BBB activates the AAR signal transduction pathway in 
the brain. 
In vitro, SLC7A5 transports not only the BCAAs but also other LNAAs, including 
phenylalanine, tyrosine and tryptophan (Napolitano et al., 2015). However, brain levels of 
these amino acids were not reduced in Tie2Cre;Slc7a5fl/fl mice but rather slightly increased 
(Figure 1D). This suggests that additional BBB-located transporters might efficiently 
compensate for Slc7a5 loss by mediating the passage of several LNAAs, but not of 
BCAAs. Indeed, RNA sequencing of mouse brain revealed a significant up-regulation of 
Slc7a1 and Slc7a3 genes (Figure 2A-B) encoding for the amino acid transporters Cat1 
and Cat3 (Fotiadis et al., 2013). This finding suggests that in vivo Cat1 and Cat3 may 
contribute to preserve brain levels of LNAAs, other than BCAAs, in the Tie2Cre;Slc7a5fl/fl 
mice.  
Furthermore, differential gene expression analysis revealed the up-regulation of 
genes implicated in serine biosynthesis in Tie2Cre;Slc7a5fl/fl mice (Figure 2B), explaining 
the modest but significant increase in brain serine level observed in the mutant animals 
(Figure 1D). An increase in the expression of genes encoding for amino acid transporters 
and serine biosynthetic enzymes has been previously linked to the activation of the AAR, 
a process implemented by individual cells to respond to amino acid deprivation (Kilberg 
et al., 2009). Consistently, RNAseq analysis of Tie2Cre;Slc7a5fl/fl mouse brain, revealed 
the up-regulation of a number of other amino acid-related genes (e.g. aminoacyl-tRNA 
synthetases) (Figure 2A-B). Among them we noticed a significant up-regulation of 
mRNAs encoding for the amino acid responsive transcription factors Atf4 and Atf5 and 
the eukaryotic initiation factor 4E binding protein 4ebp1 (Figure 2A), all part of the AAR 
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pathway. Atf4 and Atf5 have been implicated in the regulation of the central nervous 
system development and function. Specifically, Atf4 modulates synaptic plasticity and 
long-term memory formation (Chen et al., 2003), while Atf5 has been implicated in cell 
growth and development, especially in the nervous system (Angelastro et al., 2003). 
Aberrant expression of Atf4 and/or Atf5 has been implicated in cognitive dysfunctions and 
neuropsychiatric abnormalities, including altered emotional behavior (Green et al., 2008) 
and behavioral inflexibility (Trinh et al., 2012). 
Importantly, our gene expression analysis didn’t reveal any abnormality ascribable 
to increased histidine levels, suggesting that, despite histidine being the most affected 
amino acid by Slc7a5 deletion, changes in its level do not lead to severe molecular 
defects. Similarly, we didn’t detect changes attributable to alterations of other amino 
acids such as phenylalanine.  
 
Altered mRNA translation in Slc7a5 mutant mice 
Amino acid deprivation and activated AAR signaling pathway are associated with 
suppression of protein synthesis via phosphorylation of the translation initiation factor 
eIF2α. In the past few years several genes regulating mRNA translation have been 
implicated in cognitive deficits (Gkogkas et al., 2013; Santini et al., 2013). We therefore 
examined the effect of Slc7a5 knock out at the BBB on translation and associated 
pathways in the brain. 
To assess the impact of leucine and isoleucine deficiency on mRNA translation in 
the brain of Tie2Cre;Slc7a5fl/fl mice, we first performed western blot analysis of neocortical 
lysates obtained from wild-type and mutant animals. Specifically, we evaluated the 
expression and activity status of a number of proteins involved in the regulation of protein 
synthesis (Figure 2C). We observed a significant increase in the total levels of 4EBP1 
protein (Figure 2C), consistent with increased 4EBP1 mRNA levels seen in our RNAseq 
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data (Figure 2A), and of phosphorylated eukaryotic initiation factor 2 alpha (eIF2α) 
(Figure 2C), indicating that removal of Slc7a5 from the BBB and the consequent 
decrease in brain BCAA concentration may lead to the suppression of cap-dependent 
translation initiation. In contrast, in none of our experiments did we detect abnormal 
activation of the mammalian target of rapamacyin (mTOR) pathway (Figure 2C), whose 
activity was shown to be regulated by leucine levels in vitro (Wolfson et al., 2016). This 
may suggest that in vivo, under chronic leucine deficiency, the mTOR complex is 
alternatively regulated. 
To test whether abnormal regulation of 4EBP1 and eIF2α in mice lacking Slc7a5 
leads to changes in translation efficiency in the brain, we performed polysome profiling of 
wild type and Tie2Cre;Slc7a5fl/fl cortices. Importantly, in Tie2Cre;Slc7a5fl/fl mouse cortical 
lysates we observed a significant shift of ribosomes from actively translating polysomes 
toward the monosomal fraction (Figure 2D), the hallmark of decreased translation 
initiation. We conclude that BCAA shortage and associated effects of 4EBP1 levels and 
increased eIF2α phosphorylation elicit deficient translation initiation in the brain.   
Slc7a5 conditional knock out animals show motor delay and autism-related 
phenotypes 
Behavioral impairments resulting from abnormal regulation of cap-dependent 
translation have been previously described (Banko and Klann, 2008; Santini et al., 2013; 
Trinh et al., 2012). Thus, we tested Tie2Cre;Slc7a5fl/fl mice for global behavioral changes. 
Tie2Cre;Slc7a5fl/fl mice are born at Mendelian ratio and appear normal in size but display 
kyphosis (44% of mutant mice) and hind limb clasping (89% of mutant mice). In an open 
field Tie2Cre;Slc7a5fl/fl mice show reduced explorative behavior and lower velocity (Figure 
3A). Rearing, a form of vertical exploration, was significantly reduced in the 
Tie2Cre;Slc7a5fl/fl mice (Figure 3B). Nonetheless, Slc7a5 mutant mice and wild type 
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littermates have similar habituation time course (Figure S3A), suggesting that the 
diminished activity results from locomotion defects rather than a faster habituation to the 
field. Therefore we tested the Tie2Cre;Slc7a5fl/fl mice for fine motor coordination and 
locomotion problems. Indeed, Tie2Cre;Slc7a5fl/fl animals presented significant difficulties in 
the walking beam test (Figure 3C) and gait abnormalities (Figure 3D-E).  
Since in our previous work we implicated BCAA deficiency in ASD (Novarino et al., 
2012), we tested Tie2Cre;Slc7a5fl/fl for autism-like phenotypes. Tie2Cre;Slc7a5fl/fl do not 
show excessive grooming or perseverative behaviors (Figure S3B), activities which can 
be, however, severely complicated by the presence of motor deficits in the mutants. 
Thus, we tested Tie2Cre;Slc7a5fl/fl mice for social interaction abnormalities. We first 
employed a three-chamber social arena to probe the mutant animals for self-initiated 
interactions with a wild-type unfamiliar mouse. This analysis revealed that while wild-type 
mice have more close interactions with an unfamiliar mouse than an object, the 
Tie2Cre;Slc7a5fl/fl mice show no preference between these two (Figure 3F). We then 
tested juvenile animals for social play and found that Tie2Cre;Slc7a5fl/fl mice tend to stay 
farther apart from their cage-mate and display a decreased number of nose-to-nose 
contacts (Figure 3G). Finally, we measured isolation-induced ultrasonic vocalizations 
(USV) emitted by mouse pups separated from the mother. Tie2Cre;Slc7a5fl/fl pups display 
increased number of USV starting from P8 when compared with their wild-type littermates 
(Figure 3H), a behavior observed in other autism models (Gkogkas et al., 2013). 
Interestingly, the excessive number of USVs emitted by the mutant pups may be due to 
an increased repetition of a specific repertoire of vocalization patterns (Romano et al., 
2013).  
 
Inhibitory activity defects in Tie2Cre;Slc7a5fl/fl mice 
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Social interaction abnormalities have been suggested to arise from cortical 
excitation/inhibition imbalance (Yizhar et al., 2011), a correlation also observed in 
animals with abnormal regulation of translation (Gkogkas et al., 2013; Santini et al., 
2013). We evaluated synaptic function in 21 days old Tie2Cre;Slc7a5fl/fl mice using whole-
cell recordings of pyramidal neurons in layer 2/3 of the somatosensory cortex. 
Examination of synaptic transmission revealed a slight increase in the amplitude of 
miniature excitatory postsynaptic currents (mEPSCs) and a marked reduction in the 
frequency of miniature inhibitory synaptic currents (mIPSCs) (Figure 4A-B), indicating a 
significant excitation/inhibition imbalance.  
To determine whether the synaptic alterations in Tie2Cre;Slc7a5fl/fl mice are 
selective to the somatosensory cortex, we performed the same experiment in other brain 
regions. Given the locomotion abnormalities observed in Tie2Cre;Slc7a5fl/fl mice, we 
tested inputs received by the Purkinje cells. Similarly to the neocortex, Tie2Cre;Slc7a5fl/fl 
mouse cerebellar Purkinje cells display a significant reduction in mIPSC frequency 
(Figure S3C-D). 
Changes in mIPSC frequency are generally due to differences in the number of 
functional synaptic sites and/or in the presynaptic release probability at existing sites 
(changes in the GABA vesicular pool or vesicular turnover rate). Therefore, we examined 
overall brain morphology (Figure S4A), cortical layering (Figure S4B) and inhibitory 
neuron distribution (Figure S4C) and found that for these parameters somatosensory 
cortices of mutant animals were undistinguishable from the control. We further looked for 
differences in pre- and postsynaptic markers of inhibitory synapses. Importantly, we 
observed that the intensity of the vesicular GABA transporter (VGAT) staining, a marker 
for GABAergic presynaptic terminals, was lower in the somatosensory cortices of 
Tie2Cre;Slc7a5fl/fl mice (Figure 4C and Figure S4D). However, the GABAergic 
postsynaptic marker neuroligin 2 (Varoqueaux et al., 2004) appeared qualitatively and 
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quantitatively similar in the somatosensory cortex of the mutant and control mice (Figure 
4D and Figure S4E). The marked reduction of VGAT and normal neuroligin 2 protein 
levels in Tie2Cre;Slc7a5fl/fl mice were also confirmed by western blot analysis of cortical 
lysates (Figure 4E). To determine whether the reduction in VGAT staining intensity was 
due to a specific lessening of VGAT or a decline in the number of VGAT-containing 
vesicles we analyzed inhibitory synapses by electron microscopy. In agreement with the 
electrophysiology results, we detected a significant reduction of vesicle number in 
symmetric synapses in the somatosensory cortices of Tie2Cre;Slc7a5fl/fl mice compared 
with control animals (Figure 4F).  
 
Tie2Cre;Slc7a5fl/fl mutant mice resemble Bckdk knock out animals. 
The reduction in brain BCAA levels observed in Tie2Cre;Slc7a5fl/fl adult mice is 
comparable to what we measured in Bckdk-/- animals (Novarino et al., 2012). Bckdk-/- 
mice, in addition, display reduced serum BCAA levels and a marked increase in brain 
levels of several other LNAAs (Novarino et al., 2012) but normal neurotransmitter 
concentrations (Figure S5G). Thus, it remained unclear whether neurological 
abnormalities in BCKDK mutant patients and mice are due to alterations in serum or 
brain BCAA. Alternatively, the pathological conditions observed in patients carrying 
mutations in BCKDK could be due to increased brain LNAA levels.  
We compared Bckdk-/- and Tie2Cre;Slc7a5fl/fl mouse lines and observed a great 
phenotypic overlap. Similarly to Tie2Cre;Slc7a5fl/fl mice, Bckdk mutants show motor 
coordination abnormalities, autism-related behaviors, decreased mIPSC frequency 
(Figure S5A-F) and activation of the AAR pathway (Novarino et al., 2012) implying that 
Bckdk-/- and Tie2Cre;Slc7a5fl/fl mice share pathophysiological mechanisms.  
 
SLC7A5 mutations in patients with ASD and motor delay 
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Given the essential role of SLC7A5 in regulating brain BCAA homeostasis and the 
phenotypic overlap between Bckdk and Slc7a5 mutant mice, we reasoned that mutations 
in SLC7A5, could lead to ASD and motor abnormalities in humans. Thus, we 
collaboratively screened whole exome sequencing (WES) data from more than 2000 
families with documented parental consanguinity, presenting with children with various 
neurological diseases. We identified two independent families with multiple children 
affected by ASD, microcephaly and motor problems all harboring homozygous missense 
mutations in the gene SLC7A5.  
Family 1426 is a consanguineous family with two branches and 5 affected 
individuals (Figure 5A-C). WES analysis of patients 1426-5 and 1426-19 (Figure 5A) 
identified a unique shared homozygous missense variant in the SLC7A5 gene (Table S2). 
The homozygous mutation falls in a linkage pick with LOD score >4 (Figure S6A) and 
segregates with the disorder in the rest of the family (confirmed by Sanger sequencing). 
The A246V mutation changes a highly conserved alanine situated in a stretch of 
preserved amino acids predicted to be important for amino acid transport (Figure 6A-B). 
In an additional cohort of 1000 neurodevelopmental disorder patients analyzed by WES 
we identified Family 1465 including two patients with identical ASD, microcephaly and 
motor delay (Figure 5A-C) sharing a predicted deleterious homozygous mutation (Figure 
S6B) in SLC7A5 leading to the change of the conserved proline in position 375 to a 
leucine (P375L) (Figure 6A). Both genetic variants were not present in more than 200 
ethnically-matched, healthy control chromosomes, nor in our data set of over 2000 
chromosomes or in publicly available databases (Table S2).  
 
Functional assessment of SLC7A5 A246V and P375L mutations 
We mapped the two genetic variants onto a homology model of SLC7A5 (Geier et 
al., 2013). A246 is located in transmembrane helix 6 in close proximity to the extracellular 
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side and to the channel (Figure 6B). Mutation of this residue to the larger valine is 
therefore likely to impact the transporter's structure by disrupting helix–helix packing and 
ligand transport. P375 is located in transmembrane helix 9 in close proximity to the 
cytoplasmic side (Figure 6B). Proline often plays a key role in introducing kinks in helices 
and allowing conformational changes important for transporter function. Thus, mutation of 
this residue to leucine is likely to disrupt the flexibility required for transport by SLC7A5. 
To validate the functional impact of the A246V and P375L substitution we 
performed transport assays. Therefore, the recombinant A246V and P375L mutant 
proteins were successfully expressed (Figure S7A), reconstituted in proteoliposomes 
(Figure 6C-D) and tested with a series of transport assays (Napolitano et al., 2015). 
From transport time course analysis it was evident that the mutant A246V was 
virtually inactive (Figure 6C). As predicted by the homology model (Figure 6B) the 
functional defect may be ascribed to a higher steric hindrance of the valine side chain 
with respect to that of alanine. To verify this hypothesis and that the functional change 
was specifically ascribed to the pathological variant we analyzed an artificial mutant, 
A246G, (Figure S7A) in which the 246 side chain had been abolished. In contrast to the 
patient-specific A246V mutation, the A246G variant didn’t show any transport defect 
(Figure 6C and Figure S7B). To exclude that the loss of activity observed in the A246V 
mutant could be due to reconstitution failing, we assessed the efficiency of protein 
reconstitution. We found no differences in the reconstitution of the A246V mutant 
compared to the WT protein (Figure S7A). Taken together, all the data confirmed that the 
substitution of A246V was functionally disruptive. 
In contrast, the P375L mutant showed no significant variations in time dependent 
activity and external Km with respect to WT (Figure S7C-D). Owing to the location of 
P375 in an intracellular moiety of the protein (Figure 6B), we determined also the internal 
Km for this mutant (about 25 mM; 27 ± 9.9) (Figure S7E). Interestingly, the Km value was 
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roughly five times that of the WT (about 5 mM; 5.2 ± 2.3), suggesting that some 
variations in the substrate binding/translocation pathway may occur upon mutation. We 
further performed efflux experiments for evaluating possible differences in the antiport 
reaction catalyzed by SLC7A5. The measurements were performed using intraliposomal 
histidine concentration (2 mM), to create conditions similar to the intracellular 
environment. Surprisingly, the mutant P375L was mostly uncoupled. Indeed, while WT 
showed a very slow efflux in absence of external substrate, according to its antiport 
mode, the mutant unidirectional efflux was much faster with a nearly complete 
proteoliposome emptying (Figure 6D). The anomaly observed in the P375L mutant 
indicates that, in vivo, loss of intracellular SLC7A5 substrate(s) impairs the driving force 
for taking up SLC7A5 substrates. 
To further validate the functional impact of SLC7A5 mutation in the patient-specific 
genetic background, we obtained human dermal fibroblasts from two affected and a few 
unaffected members of Family 1426 and Family 1465 and performed [3H]-leucine uptake 
assay (Sinclair et al., 2013). SLC7A5 transcript is expressed in human dermal fibroblasts 
and its level is not affected by the missense mutations (Figure S7F). Cells carrying the 
homozygous A246V or P375L variant, however, show a significant reduction in [3H]-
leucine uptake when compared with control cells (Figure 6E). Thus, the substitution of 
the SLC7A5 alanine 246 into a valine, or of the proline 375 into a leucine, is sufficient to 
significantly reduce the SLC7A5-mediated BCAA uptake. 
 
BCAA intracerebroventricular injections rescue neurological abnormalities in adult 
Slc7a5 mutant mice  
The identification of ASD patients carrying mutations in the SLC7A5 gene 
prompted the question whether this condition is potentially treatable. Therefore, we 
injected leucine and isoleucine stereotaxically into the brain of adult Tie2Cre;Slc7a5fl/fl 
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mice for 3 weeks (Figure 7A). Injected mice were then tested for some of the behavioral 
phenotypes described in Figure 3 and brain amino acid levels. Notably, after 3 weeks of 
i.c.v. leucine and isoleucine delivery (Figure 7A) their brain level was normalized (Figure 
7B and Table S3) and the mutant mice showed a significant improvement in 
neurobehavioral abnormalities. Specifically, we observed a decreased number of 
Tie2Cre;Slc7a5fl/fl mice showing the clasping (50% of injected vs 89% of non injected 
mutant mice) and the kyphosis phenotype (25% of injected vs 44% of non injected 
mutant mice). Most importantly, we could not detect any difference between treated 
Tie2Cre;Slc7a5fl/fl and wild type mice in the open field test neither in velocity and distance 
moved nor in the number of rearings (Figure 7C). The gait of the injected 
Tie2Cre;Slc7a5fl/fl mice was improved with a complete normalization of the sway length 
(Figure 7D). Importantly, wild type animals injected with the leucine/isoleucine mixture 
were indistinguishable from the non-injected animals of the corresponding genotype 
(Figure 7C-D), indicating that leucine and isoleucine specifically improve behavior of 
Slc7a5 mutants. Worth mentioning is the fact that the rescue of the social and 
vocalization abnormalities could not be tested given technical issues presented by the 
presence of the implanted pump and the size of the animals (see STAR methods). 
Although further tests are required to determine the extent and efficacy of the 
treatment, our data suggest that certain neurobehavioral abnormalities observed in 
Slc7a5 mutants can be rescued by i.c.v. administration of leucine and isoleucine in 
adulthood. Even if we cannot entirely disregard a role of the increased level of other 
amino acids, these results support the idea that the reduction in brain leucine and 
isoleucine levels is the determinant factor in the appearance of the neurological 
phenotypes observed in humans and mice lacking SLC7A5 expression. 
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DISCUSSION 
Although SLC7A5 has been described as a BBB amino acid transporter, studies 
accurately verifying its expression or examining its function at the BBB are completely 
missing in the literature. Moreover, transport studies were performed using only in vitro 
systems thus lacking the expression of other carriers with possibly overlapping substrates 
and its physiological importance remained almost completely undetermined.  
Our study shows that SLC7A5 loss of function leads to ASD and motor 
dysfunctions in humans and mice. This fits with our previous work in which we have 
shown that mutations implicated in abnormal BCAA catabolism lead to ASD and fine 
motor coordination problems (Novarino et al., 2012). Along the same line, an increase in 
the brain levels of these same amino acids leads to the maple syrup urine disorder, 
characterized by cognitive dysfunctions, seizures and hypotonia (Menkes et al., 1954; 
Zinnanti et al., 2009). Although we acknowledge that ASD due to SLC7A5 mutations may 
be an extremely rare condition, the present study indicates that fine-tuning of brain BCAA 
and LNAA concentrations is key for normal brain function and that mutations affecting 
genes contributing to BCAA homeostasis and the downstream signaling cascade may 
underlie a larger subgroup of ASD. In addition, this work has several important 
pathophysiological implications. 
We show that Slc7a5 expression at the BBB is particularly important to set a 
correct brain BCAA concentration. In fact, a lack of Slc7a5 expression at the BBB leads 
to a significant reduction in brain BCAA levels, particularly leucine and isoleucine. 
Surprisingly, we didn’t detect significant reductions in the brain levels of the other LNAAs, 
which in the mutant mice are rather slightly increased, indicating that additional carriers 
are involved in their transport. Among the most altered amino acids, beside leucine and 
isoleucine, we detected histidine, suggesting that this amino acid may have a special role 
in the function of the transporter. Noteworthy, the normal brain histamine levels (Figure 
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S2C) as well as the RNAseq data obtained from mutant mice exclude an alteration of 
histaminergic transmission. Moreover, abnormally high serum and cerebrospinal fluid 
histidine levels have been reported in healthy individuals implying that increased histidine 
concentration is non-pathological (Lam et al., 1996).  
Furthermore, we show that deletion of Slc7a5 from the BBB leads to activation of 
the AAR pathway and reduced cap-dependent translation. How exactly abnormal 
regulation of translation leads to the observed phenotypes in SLC7A5 mutant humans 
and mice remains to be investigated. However, we observed that inhibitory neurons may 
be more sensitive to altered amino acid levels as Atf5, a key molecule in the AAR 
pathway, has been reported to be preferentially expressed in GABA-synthetizing neurons 
(Zeisel et al., 2015). Accordingly, we found that deletion of Slc7a5 from the BBB is 
sufficient to reduce cortical inhibitory activity, resulting in cortical excitation/inhibition 
imbalance and probably causing the observed neurological complications. Similarly, most 
of the functionally characterized ASD-mutations lead to an imbalance in the 
excitation/inhibition ratio. Thus, drugs acting on GABA transmission are considered an 
opportunity for the treatment of ASD and epilepsy (Braat and Kooy, 2015). It is therefore 
tempting to reason that identifying the rules by which simple molecule such as the 
BCAAs may regulate GABAergic transmission might have a crucial impact on the 
development of novel therapeutic strategies for ASD. 
Notably, besides representing a new subgroup of ASD, BCAA-related ASD may 
also represent a group of treatable conditions. Indeed, BCAA dietary administration in 
BCKDK null mice and humans (Novarino et al., 2012), as well as leucine and isoleucine 
i.c.v. injection in adult Tie2Cre;Slc7a5fl/fl mice lead to a significant improvement of the 
neurobehavioral abnormalities.  
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STAR ★ METHODS  
 
Detailed methods are provided in the online version of this paper and include the 
following:  
 
x KEY RESOURCES TABLE 
x CONTACT FOR REAGENT AND RESOURCE SHARING 
x EXPERIMENTAL MODEL AND SUBJECT DETAILS 
o Mice 
o Human subjects and sample collection 
o Cell lines  
o Protein model  
x METHOD DETAILS 
o Amino acid analysis 
o RNA-sequencing  
o Western blot  
o Polysome profiling  
o Immunohistochemistry  
o Nissl staining 
o Electrophisiology  
o Electron microscopy  
o Behavioral studies 
o Intracerebroventricular dye injection 
o Serial surgical implantation of cannula and osmotic pumps  
o Whole exome sequencing, homozygosity profile and variant prioritization 
o Sanger sequencing  
o Leucine uptake assay 
o Cloning, mutagenesis and expression of the human SLC7A5 wild-type and 
mutants 
o Purification of human SLC7A5 wild-type and mutants  
o Reconstitution of human SLC7A5 wild-type and mutants in 
proteoliposomes  
o Transport measurements 
o Ultracentrifugation of proteoliposomes  
x QUANTIFICATION AND STATISTICAL ANALYSIS  
o Amino acid data 
o RNA-sequencing  
o Protein data 
o Imunohistochemistry  
o Neuronal data 
o Electron microscopy  
o Behavior 
o Transport measurement data 
x DATA AND SOFTWARE AVAILABILITY 
o Data resources 
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FIGURE LEGENDS 
Figure 1. Slc7a5 mediates BCAA flux at the BBB  
(A) Representative images showing Slc7a5 (green) localization at the BBB in control 
animals (Slc7a5fl/fl, left) and its complete deletion in endothelial cells of the BBB in Cre 
positive mice (Tie2Cre;Slc7a5fl/fl, right). Immunostainings were performed in cortical slices 
at embryonic day 14.5 (E14.5 top), postnatal day 2 (P2, middle) and adulthood (>P40, 
bottom). Nuclei were stained with DAPI (blue). (B-D) Brain amino acid levels in 
Tie2Cre;Slc7a5fl/fl mice at E14.5 (B), P2-14 (C) and >P40 (D). Levels of amino acids were 
normalized on protein concentration and shown as fold change (log2 transformed) to 
levels in age-matched controls. In red are represented the amino acids with a fold 
change >1.3 and P value <0.05 (n>4 mice/genotype/time point).  
See also Figure S1, S2 and Table S1. 
 
Figure 2. Activation of the amino acid response pathway in the brain of Slc7a5 
mutant mice  
(A) RNA sequencing of adult brain in Tie2Cre;Slc7a5fl/+ and Tie2Cre;Slc7a5fl/fl mice 
revealed 131 differentially expressed genes (FDR-adjusted P-value ≤ 0.05). The heat 
map displays log transformed count data normalized to library size. Genes expressed at 
lower levels in Tie2Cre;Slc7a5fl/fl (40 genes) are displayed at the top and genes up-
regulated in Tie2Cre;Slc7a5fl/fl (91 genes) are shown at the bottom. Zoomed rows on the 
right emphasize differentially expressed genes associated with amino acid import 
(GO:0089718), tRNA aminoacylation (GO:0006418) and amino acid response, 
respectively (n=3 mice/genotype). 
(B) Results of GO Enrichment analysis on the set of 131 differentially expressed genes. 
Terms are sorted according to P-value with the most significantly enriched terms at the 
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top: GO terms for molecular functions (GO:MF, left, blue); GO terms for biological 
processes (GO:BP, right, green). The length of each bar indicates the P-value while the 
width indicates the amount of genes in the set associated with the term. 
(C) Western blot analysis from cortical lysates of Tie2Cre;Slc7a5fl/+ (control) and 
Tie2Cre;Slc7a5fl/fl mice, indicating that mutants exhibit increased phospho-eIF2α and total 
4EBP1 protein levels but normal levels of total eIF2α, phospho-4EBP1, phospho-S6K, 
S6K, phospho-eIF4E and eIF4E. Tubulin was used as internal control. Representative 
blots (left) and fold change ratio (right); *P<0.05 (means ± SEM; n≥4 mice/genotype).  
(D) Polysome profile from cortical lysates of control and Tie2Cre;Slc7a5fl/fl mice. Typical 
tracings indicating positions of 40S, 60S and 80S ribosome peaks and polysome 
(P)/monosome (M) ratio quantifications; ***P<0.001 (right inset: means ± SEM; n=10 
control and n=9 mutant mice). 
 
Figure 3. Neurobehavioral abnormalities in the Tie2Cre;Slc7a5fl/fl mice  
(A-D) Decreased exploratory behavior and locomotion abnormalities in the 
Tie2Cre;Slc7a5fl/fl mice. (A) Open field test. Representative trajectories (left) and 
quantification of the total distance moved (middle) and the velocity (right) indicating that 
Tie2Cre;Slc7a5fl/fl mice are outperformed by controls; **P<0.01 (means ± SEM; n=10 
mice/genotype). (B) Comparison of the number of rearings pointing out deficiencies in the 
mutants; **P<0.01 (means ± SEM; n=10 mice/genotype) (C) Walking beam performance 
on training days (Day 1, Day 2) and on the three trials of the test day (Day 3), showing 
elevated latency to cross the beam in the mutants; *P<0.05, **P<0.01 (means ± SEM; 
n=7 mice/genotype). (D) Representative images of control (left) and Tie2Cre;Slc7a5fl/fl 
strides (right) in the gait test. Forepaw (red) and hindpaw (blue). (E) Altered gait of the 
Tie2Cre;Slc7a5fl/fl mice is evidenced by inter-genotype comparison of stride, sway and 
 25 
stance length quantifications; *P<0.05, **P<0.01, ***P<0.001 (means ± SEM; n=7 
mice/genotype).   
(F) Three chamber social interaction test (left) and quantifications (right) of the number of 
contacts with the caged mouse (M) or with the caged object (O) revealing abnormal 
social interaction pattern in the mutant mice (mutants show no preference for the M over 
the O, as opposed to controls); **P<0.01, N.S. not significant (means ± SEM; n=12 
mice/genotype).  
(G) Juvenile Tie2Cre;Slc7a5fl/fl mice display fewer reciprocal social interactions. Slc7a5 
mutant mice tend to stay farther apart from their cage mate (heat-map and bottom left 
graph) and exhibit fewer nose-to-nose contacts (bottom right graph). WT= Slc7a5fl/+; KO= 
Tie2Cre;Slc7a5fl/fl. *P<0.05 (means ± SEM; n=8 mice/genotype).  
(H) Isolation induced USV at various postnatal days show that Tie2Cre;Slc7a5fl/fl mice emit 
an increased number of calls starting at P8. *P<0.05 (means ± SEM; n=10 
mice/genotype).  
See also Figure S3.  
Figure 4. Excitation/inhibition imbalance in Tie2Cre;Slc7a5fl/fl somatosensory cortex  
(A-B) Left: Representative mEPSC (A) and mIPSC (B) recordings from Tie2Cre;Slc7a5fl/+ 
and Tie2Cre;Slc7a5fl/fl somatosensory cortex (SCX) layers 2-3 pyramidal neurons; Right: 
Cumulative probability distributions of peak amplitudes and inter-event intervals of 
mEPSC (A) and mIPSC (B) in the two genotypes. Insets: quantifications of mean 
amplitudes and mean frequencies of the corresponding currents, with significant 
differences in mutants versus controls. D=0.093, P<10-11 (mEPSC amplitudes) and 
D=0.099, P<10-15 (mIPSC interevent intervals); (means ± SEM, ncells/nanimals/genotype: 
14/7/Tie2Cre;Slc7a5fl/+ and 13/5/Tie2Cre;Slc7a5fl/fl (mEPSC); 16/7/Tie2Cre;Slc7a5fl/+ and 
18/5/Tie2Cre;Slc7a5fl/fl (mIPSC).  
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(C) Representative confocal images of VGAT-positive synaptic puncta (green) in control 
(left) and Tie2Cre;Slc7a5fl/fl (right) cortical sections displaying decreased staining intensity 
in the mutants. Nuclei were stained with DAPI (blue).  
(D) Confocal imaging of cortical sections labeled for Neuroligin 2 (NLGN2, red) of control 
(left) and Tie2Cre;Slc7a5fl/fl (right) animals revealing no difference between genotypes. 
Nuclei were stained with DAPI (blue). Scale bar as in (C). 
(E) Western blot analysis from cortical lysates indicating decreased VGAT (top) and 
similar NLGN2 protein levels (middle) in Tie2Cre;Slc7a5fl/fl mice compared with controls. 
GAPDH (bottom) was used as internal control.  
(F) Electron microscopy imaging of the SCX layers 2-3 showing that Tie2Cre;Slc7a5fl/fl 
mice have a decreased area of GABAergic boutons and decreased density of vesicles 
per bouton. Typical micrograph images (left), summary graphs of presynaptic area 
(middle) and vesicle density (right); ***P<0.001 (means ± SEM; nsynapses/genotype: 
27/control and 22/mutant).  
See also Figure S4 and S5.  
Figure 5. Mutations in the human SLC7A5 lead to ASD and motor deficits  
(A) SLC7A5 mutations identified in families 1426 and 1465 in individuals with ASD, motor 
deficits and microcephaly. Pedigrees 1426 and 1465 display first-cousin consanguinity, 
five and two affected patients (solid symbols) respectively and unaffected members 
(open symbols) 
(B) MRI from one patient for each family showing microcephaly and thin corpus callosum 
but normal axial T1 sequence of the brain. Control child brain MRIs were obtained from 
unrelated individuals.   
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(C) Clinical presentation of patients from family 1426 and 1465. HC, head circumference; 
SD, standard deviation; GTC, generalized tonic clonic; N/A not available; CC, corpus 
callosum. 
See also Table S2. 
 
Figure 6. A246V and P375L mutations compromise SLC7A5 function  
(A) Conservation of the SLC7A5 A246 and P375 in several species.  
(B) Side, top and bottom views of the predicted structure of SLC7A5 in complex with 
tryptophan showing SLC7A5 backbone atoms (gray ribbon), atoms of the residues 
constituting the missense mutations (yellow spheres) and the ligand tryptophan (green 
sticks); oxygen atoms (red) and nitrogen atoms (blue).  
(C) SLC7A5 wild-type, A246V and A246G mutants over-expressed and purified by fast 
protein liquid chromatography were reconstituted in proteoliposomes. Transport is 
followed as uptake (red arrow) of external [3H]His in exchange with internal His. 
Transport was started by adding external 5 µM [3H]His at time zero to proteoliposomes 
containing 10 mM His reconstituted with SLC7A5-WT (○), SLC7A5-A246V ( ) or 
SLC7A5-A246G (●) and stopped at the indicated times (means ± SD; n=5 experiments).  
(D) Time dependence of [3H]His efflux from proteoliposomes reconstituted with SLC7A5-
WT or SLC7A5-P375L was measured. Proteoliposomes reconstituted with SLC7A5-WT 
(○, ●) or SLC7A5-P375L ( , ), containing 2 mM His were radioactivity-preloaded. Efflux 
was measured in absence (○, ; uniport) or presence of external 1 mM His (●, ; 
antiport). Percentage of His efflux was calculated with respect to time 0 (means ± SD; 
n=4 experiments).  
(E) Radio-labeled leucine ([3H]Leu) transport analysis in human fibroblasts from affected 
(A) and unaffected (U) members of families 1426 and 1465 illustrating a significant 
reduction in leucine uptake by the cells of affected patients. Specificity of leucine uptake 
 28 
was assessed by competition with 10mM cold leucine (Leu) or 10 mM 2 BCH; ***P<0.001 
(means ± SEM; N≥3 experiments performed with fibroblasts from two patients and one 
healthy control/family). 
See also Figure S7.  
Figure 7. Normalization of Tie2Cre;Slc7a5fl/fl mouse behavior after leucine and 
isoleucine i.c.v. administration  
(A) Timeline of treatment and HPLC and behavioral tests.  
(B) Brain levels of leucine (left) and isoleucine (right) in age-matched animals receiving 
(+) or not receiving (-) the i.c.v. treatment. Amino acid levels were normalized to protein 
concentration and to wild-type levels. **P<0.01, ***P<0.001 (means ± SEM; n=8 
mice/genotype).  
(C) Quantification of the total distance moved (left), velocity (middle) and number of 
rearings (right) in the open field revealing similar behavior in treated (+) Tie2Cre;Slc7a5fl/fl 
mice and non-treated (-) or treated (+) controls (Tie2Cre;Slc7a5fl/+) but significant 
differences with non-treated (-) Tie2Cre;Slc7a5fl/fl mice; *P<0.05, **P<0.01 (means ± SEM; 
n=10 (-) control, n=4 (+) control, n=11 (-) mutant and n=8 (+) mutant).  
(D) Similar sway length in treated (+) mutant mice and non-treated (-) or treated (+) 
control (Tie2Cre;Slc7a5fl/+) animals but significant difference with non-treated (-) 
Tie2Cre;Slc7a5fl/fl mice; **P<0.01 (means ± SEM; n=10 (-) control, n=4 (+) control, n=11 (-) 
mutant and n=8 (+) mutant).  
See also Table S3.  
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SUPPLEMENTAL FIGURE LEGENDS 
 
 
Figure S1. Slc7a5 and Tie2Cre expression at the BBB, Related to Figure 1  
(A) Representative images of cortical slices stained with Slc7a5 (left) and the endothelial 
cell marker MECA 32 (middle) antibodies. The merged image (right) displays the co-
localization of the two markers in control animals.  
(B) Human mRNA expression profile in different tissues (top) reveals almost exclusive 
expression of SLC7A5 in the cortex. Sampled tissues are: cortex, kidney, skeletal 
muscle, lung, spleen, testis, liver. GAPDH (bottom) was used as internal control.  
(C) Representative Slc7a5 (green) immunostained mouse tissue slices from control 
Slc7a5fl/fl (top) and mutant Tie2CreSlc7a5fl/fl (bottom) animals. Tissues were sampled from 
adult (>P40) mice and they include: liver (left), lung (middle) and kidney (right). Nuclei 
were stained with DAPI (blue).  
(D) Tie2-driven Cre recombinase expression in the BBB was verified by crossing Tie2Cre 
mice with the reporter line Gt26Sor. Gt26Sor mice express cell-membrane localized red 
fluorescencent protein (RFP) in widespread cells and tissues prior to Cre recombinase 
exposure and cell membrane-localized green fluorescencent protein (GFP) in Cre 
recombinase expressing cells. Note GFP staining in the endothelial cells of the BBB 
(right). Images were obtained from the cerebral cortex of 2 days old (P2) mice. 
 
 
Figure S2. Slc7a5 does not transport neurotransmitters, Related to Figure 1  
(A-B) Left: Schematic of the in vitro transport assay - transport followed as uptake (A) of 
external [3H]His in exchange to internal substrate (S) or as efflux (B) of internal [3H]His in 
exchange with external substrate (S) in proteoliposomes with reconstituted SLC7A5 
protein. Right: SLC7A5-mediated His uptake (A) and efflux (B) analysis indicates the 
inability of SLC7A5 to transport the tested neurotransmitters. Transport was started by 
adding 5 µM [3H]His at time 0 to proteoliposomes containing 10 mM His, or the tested 
neurotransmitter,  reconstituted with human SLC7A5 and stopped at the indicated times. 
Percentage of His efflux (B, % Residual activity) was calculated with respect to time 0 for 
each experimental condition. His-histidine; L-DOPA, L-3,4-dihydroxyphenylalanine; Ach-
acethylcholine. 
(C) Normal brain neurotransmitter levels in brain lysates of Tie2Cre;Slc7a5fl/fl (red bars) 
mice. Neurotransmitter levels were quantified by HPLC and normalized on protein 
concentration and on control (Tie2Cre;Slc7a5fl/+, grey bars) littermate levels (means ± SD; 
n=4 mice per genotype). 
 
 
Figure S3. Behavioral and electrophysiological alterations in Tie2Cre;Slc7a5fl/fl mice, 
Related to Figure 3 and 4  
(A) Tie2Cre;Slc7a5fl/fl (red) and Tie2Cre;Slc7a5fl/+ (grey)  show similar habituation kinetics in 
the open field. Distance moved in the open field was analyzed in 5-minute bins over the 
course of 20 minutes. Tie2Cre;Slc7a5fl/fl mice moved less at all given points *P<0.05, 
**P<0.01 (means ± SEM; n=10 mice per genotype). 
(B) Marble burying test shows no significant difference between the number of marbles 
buried by the control Tie2Cre;Slc7a5fl/+ and the mutant Tie2Cre;Slc7a5fl/fl; N.S., not 
significant (means ± SEM; n=10 mice per genotype; circles represent individual values).  
(C-D) Left: Representative mEPSC (B) and mIPSC (C) recordings from Tie2Cre;Slc7a5fl/+ 
(grey) and Tie2Cre;Slc7a5fl/fl (red) cerebellar Purkinje cells. Right: Cumulative probability 
distributions of peak amplitudes and interevent intervals of mEPSC (B) and mIPSC (C) in 
the two genotypes. Insets: quantifications of mean amplitudes and mean frequencies of 
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the corresponding currents, along with absolute P values. Significant reduction in mIPSC 
mean frequency in mutants versus controls is indicated. Result confirmed by cumulative 
probability distribution analysis, Kolmogorov-Smirnov test: D=0.109; *P<0.05 (means ± 
SEM; ncells/nanimals/genotype: 7/3/Tie2Cre;Slc7a5fl/+ and 6/3/Tie2Cre;Slc7a5fl/fl; circles indicate 
individual values). mEPSCs and mIPSCs were recorded from the same cell.  
 
 
Figure S4. Absence of gross alterations in brain architecture of Tie2Cre;Slc7a5fl/fl 
mice, Related to Figure 4 
(A) Nissl staining of sagittal sections of adult mouse brain indicating no differences in 
gross morphology between the control Tie2Cre;Slc7a5fl/+ and mutant Tie2Cre;Slc7a5fl/fl 
mice. 
(B) Immunostaining of Cux1 (green, upper layer neurons) and Ctip2 (red, lower layer 
neurons) shows similar cortical layer distribution in the two genotypes.  
(C) Representative images (left) and quantifications (right) indicating similar numbers of 
parvalbumin- (top), somatostatin- (middle) and calretinin- (bottom) positive interneurons 
in the cortices of wild-type and mutant mice; N. S., not significant (means ± SEM; n=3 
mice per genotype; filled circles indicate individual values). Nuclei were stained with DAPI 
(blue). 
(D) Fluorescence intensity quantification of VGAT puncta in control Tie2Cre;Slc7a5fl/+ 
compared to mutant Tie2Cre;Slc7a5fl/fl mice; **P<0.01 (means ± SEM; n=3 mice per 
genotype).  
(E) Fluorescence intensity quantification of NLGN2 puncta displaying no difference 
between control Tie2Cre;Slc7a5fl/+ and mutant Tie2Cre;Slc7a5fl/fl mice; N.S., not significant 
(means ± SEM; n=3 mice per genotype).  
  
Figure S5. Phenotypic characterization of Bckdk-/- animals, Related to Figure 4 
(A) Representative open field trajectories (left) and quantification of the total distance 
moved (middle) and the velocity during exploration (right); **P<0.01 (means ± SEM; n=25 
mice per genotype; circles indicate individual values).  
(B) Comparison of the number of rearings (anxiogenic forms of vertical exploration) of the 
two genotypes during the open field test, pointing out deficiencies in the mutants; 
***P<0.001 (means ± SEM; n=18 mice per genotype; circles indicate individual values).  
(C) Performance on the walking beam throughout the training days (Day1, Day2) and the 
three trials on the test day (Day3), showing elevated latency to cross the beam in the 
mutants; *P<0.05 (means ± SEM; n=23 mice per genotype).  
(D) Stride length quantifications in the gait test reveal locomotor deficiencies in Bckdk-/- 
mice; *P<0.05 (means ± SEM; n=20 mice per genotype; circles indicate individual 
values).   
(E) Bar graph quantifications of the number of contacts with the caged mouse (M) or with 
the caged object (O) in the three-chamber sociability test, revealing abnormal social 
interaction pattern in the mutant mice (mutants show no preference for the M over O, as 
opposed to controls); ***P<0.001, N.S., not significant (means ± SEM; n=16 mice per 
genotype; circles indicate individual values). 
(F) Left: Representative mEPSC (top) and mIPSC (bottom) recordings from control 
Bckdk+/+ (black) and Bckdk-/- (red) somatosensory cortex layers 2-3 pyramidal neurons; 
Right: Cumulative probability distributions of peak amplitudes and interevent intervals of 
mEPSC (top) and mIPSC (bottom) in the two genotypes. Insets: quantifications of mean 
amplitudes and mean frequencies of the corresponding currents. The significant 
reduction in mIPSC mean frequency detected in the mutants versus controls is indicated 
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as absolute P value: *P<0.05 (means ± SEM; n>3 animals/genotype; number of recorded 
cells is noted on each column). 
(G) Normal brain neurotransmitter levels in brain lysates of Bckdk-/- mice. 
Neurotransmitter levels were quantified by HPLC and normalized on protein 
concentration and on control littermate (Bckdk+/+) levels;  N.S., not significant (means ± 
SEM; n=4 mice per genotype). 
 
 
Figure S6. Genotyping information of Family 1426 and 1465, Related to Figure 5 
(A) Homozygosity map for Family 1426. Blocks of homozygosity are depicted as peaks. 
The red arrow indicates the interval that includes SLC7A5.  
(B) Sequence chromatograms of all members of Family 1465 including the affected 
siblings and the carrier parents. 
 
 
Figure S7. Characterization of SLC7A5-A246V, -A246G and SLC7A5-P375L 
mutants, Related to Figure 6 
(A) Western blot analysis of the indicated SLC7A5 mutants in comparison with the WT 
protein reconstituted in proteoliposomes (top and middle panels). To evaluate the 
efficiency of reconstituted SLC7A5, proteoliposomes reconstituted with WT or SLC7A5 
A246V were separated from liposomes (not containing reconstituted protein) by 
ultracentrifugation; blots of reconstituted proteins (proteoliposome) and of the purified 
protein before reconstitution (purified) are included in the bottom panel.  
(B) SLC7A5-WT and SLC7A5-A246G-mediated transport rate (upon reconstitution in 
proteoliposomes) is dependent on external His concentration showing similar patterns for 
the two proteins. [3H]-His was added at the indicated concentration to proteoliposomes 
containing 10 mM His, and transport stopped after 10 min (i.e. within the initial linear 
range of the time course). Data were fitted according to Lineweaver–Burk plot as 
reciprocal transport rate vs reciprocal His concentration (means ± SD; n=3 independent 
experiments). 
(C) Time-course of the transport mediated by SLC7A5-WT and P375L reconstituted in 
proteoliposomes, showing that the P375L mutant protein is functional. Transport was 
started by adding 5 µM [3H]His at time zero to proteoliposomes containing 10 mM His 
reconstituted with WT- or P375L- SLC7A5 and stopped at the indicated times as 
described in the Experimental Procedure (means ± SD; n=5 independent experiments). 
(D) Rate of SLC7A5-mediated transport dependent on external His concentration. 
Transport rate was measured adding [3H]His at the indicated concentration to 
proteoliposomes containing 10 mM His reconstituted with WT- or P375L-SLC7A5 protein. 
Transport was stopped after 10 min, i.e., within the initial linear range of the time course.  
Data were fitted according to Lineweaver–Burk plot as reciprocal transport rate vs 
reciprocal His concentration. (Means ± SD; n=3 independent experiments). 
(E) Rate of SLC7A5-mediated transport dependent on internal His concentration. 
Transport rate was measured adding 50 µM [3H]His to proteoliposomes, containing the 
indicated His concentrations, reconstituted with WT- or P375L- SLC7A5 protein. 
Transport was stopped after 10 min, i.e., within the initial linear range of the time course.  
Data were fitted according to Lineweaver-Burk (or Michaelis-Menten) plot as reciprocal 
transport rate vs reciprocal His concentration. (Means ± SD; n=3 independent 
experiments). 
(F) Representative immunoblot showing SLC7A5 transcript expression in human dermal 
fibroblasts; expression level is not affected by the A246V missense mutation (n=3 
independent experiments). 
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STAR   METHODS  
 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
 
Further information and requests for reagents may be directed to, and will be fulfilled by 
the lead author G.N. (gnovarino@ist.ac.at).  
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS  
 
Mice   
Experiments were performed in accordance with protocols approved by the Institutional 
Animal Care and Use Committee at IST Austria. Generation of the Tie2-Cre and Slc7a5 
floxed lines has been described previously (Kisanuki et al., 2001; Sinclair et al., 2013). 
For all experiments we made use of littermates derived from crossing Cre negative 
Slc7a5fl/fl females with Cre positive Slc7a5fl/+ males. Mice were backcrossed to the N10 
generation in C57BL/6J mice. Overall, Tie2Cre;Slc7a5fl/fl transgenic animals were viable 
and fertile. Mice were housed together with their littermates in groups of 3-4 animals per 
cage and kept on a regular 12 h light/dark cycle (7:00-19:00 light period). Food and water 
were available ad libitum. Experiments were carried out under pathogen-free conditions 
and health status of the mouse line was routinely checked by a veterinary. Experiments 
were carried out with randomly chosen littermates of the same sex. Both males and 
females were used with exception of the three-chamber test for which only males were 
employed. The genotype, age and developmental stage of the employed animals are 
specified separately for each experiment. For all the experiments the animals were drug 
and test naïve but when possible mice were employed for different tests starting with the 
less aversive test (see behavioral study description).  
 
Human subjects and sample collection 
Patients were identified from a cohort of over 2500 families, with at least one member of 
the family displaying a childhood onset neurological condition of likely genetic origin, from 
several world-wide recruitment efforts targeting patients with intellectual disability, 
structural brain diseases or neurodevelopmental disorders. Recruitment was focused in 
the major population centers of the Middle East including Morocco, Libya, Egypt, Saudi 
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Arabia, Kuwait, UAE, Oman, Jordan, Pakistan, Turkey and Iran, with consanguinity rates 
(i.e. rate of marriage between first or second cousins) of approximately 50% compared 
with <1% is US and Western Europe. Among the recruited cohort, consanguinity was 
present in 63% of parents, suggesting some bias in sampling towards those with affected 
children due to recessive disease. Sampling was performed on both parents and all 
available genetically informative siblings to include affected and unaffected members, as 
well as extended family members if appropriate, consistent with IRB guidelines. All 
patients were evaluated directly by one of the co-authors with specialty training in 
neurology, child neurology and/or clinical genetics, and in accordance with local medical 
practices. All patients/families enrolled in IRB approved protocols based at referral 
institutions, and each family provided consent for study. Sequencing was performed on at 
least one but sometimes two affected or the father-mother-affected trio per family. 
Families 1426 and 1465 were identified and employed in this study because of 
comprising patients with homozygous disruptive mutations in the SLC7A5 gene. 
Diagnosis of autism was set prior to whole exome sequencing and according to 
internationally accepted guidelines (DSM-V and CARS interview). Videos documenting 
the neurological examination and clinical features documentation were obtained in most 
of the cases. 
 
Patient 1426-5 (female) was born at full term by normal delivery to a healthy mother after 
an uneventful pregnancy. There was no history of intellectual disability or epilepsy in the 
family. No chromosomal abnormalities were identified. Occipito-frontal head 
circumference (OFC) was -2 SD at birth and -5 SD in late childhood. The girl never 
learned to walk; she shows increased tone, clonus and dystonia since 5 years of age. 
She can bear some weight on the legs with support. She shows impaired social 
interaction, eye-to-eye gaze, and restrictive behaviors but has a social smile.  She can 
understand simple commands but does not have speech.  CARS (childhood autism 
rating scale) score at the age of 33 was 31 (autism cutoff 30). She has no seizures and 
she does not take any medication.  She has no other health problems. There are no 
progressive features.  
 
Patient 1426-6 (male), 1426-8 (female), 1426-16 (male) and 1426-19 (male) presentation 
and history are essentially similar to patient 1426-5. In late childhood all the patients 
present with various degrees of microcephaly (see Figure 5B). CARS score for patients 
1426-6 and 1426-8 were 31 and 34 at the age of 17 and 12 years, respectively. Patient 
1426-16 died of an unrelated cause during the preparation of this manuscript; therefore 
there is not updated information for this patient. 
Importantly, all the affected individuals of family 1426 have normal plasma amino acid 
concentrations (Table S5).   
 
Patient 1465-3 (male) was the second child, born to consanguineous parents (who were 
first cousins) at full term, after an uneventful pregnancy. He presented with intractable 
epilepsy and neurodevelopmental delay during his infancy period. The medical history of 
the family is notable for a previous case of microcephaly. The patient began walking at 
48 months. Upon examination, his weight, height and head circumference measurements 
were under 3rd percent, he was hypotonic and microcephalic with slightly dysmorphic 
face. He was unable to speak. He had joint laxity in his lower extremities and pes planus 
in both feet. 
Patient 1465-4 (male) has also been born at full term after a normal pregnancy, but 
displayed similar symptoms of abnormal development. Like his brother, he was brought 
to medical attention due to intractable seizures, which started when he was six months 
old. When he was 24-months-old he was able to sit without support. He never developed 
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speech. At the time of examination, he was found to have microcephaly, hypotonia, 
slightly dysmorphic face, scoliosis, decreased subcutaneous fatty tissue and joint laxity in 
his hands and lower extremities. He was unable to speak or write, and was able to walk 
with support. 
 
Cell lines 
Mutant and control fibroblasts were generated from explants of dermal biopsies following 
informed consent under protocols approved by the University of California San Diego or 
Yale University. Primary skin fibroblasts from affected and unaffected passage-matched 
controls were cultured in Dulbecco’s Modified Eagle Medium supplemented with 10% 
fetal bovine serum and 1X Penicillin-Streptomycin. Cell lines were maintained in a 5% 
CO2 incubator at 37oC. Cell lines were routinely tested to exclude Mycoplasma 
contaminations.  
 
Protein model 
The SLC7A5 homology model was built based on the X-ray structure of the 
agmatine/arginine AdiC transporter from E. Coli in the outward-occluded arginine-bound 
conformation (PDB identifier 3L1L (Gao et al., 2010)). SLC7A5 and AdiC are members of 
the amino acid-polyamine-organocation (APC) transporter superfamily and exhibit 
sequence identity of about 22% (Geier et al., 2013; Saier et al., 2009). We used PyMOL 
to visualize the model and predict possible mutation effect on the protein structure 
(DeLano, 2002). 
 
METHOD DETAILS  
 
Amino acid analysis  
 
Plasma amino acid analysis in mice 
Adult mice were euthanized by cervical dislocation, decapitated and blood was collected 
(200 µL) from their trunks into commercially available anticoagulant treated tubes (e.g. 
heparin tubes Vacuette, Greiner Bio One). Cells were removed from plasma by 
centrifugation for 10 min at 2000 X g at 4°C. Following centrifugation the plasma 
supernatant was transferred into clean polypropylene tubes and kept at -70°C until 
assayed for amino acid concentrations by High Performance Liquid Chromatography 
(HPLC). Mouse plasma amino acid values reported in Table S1 represent mean ± SEM 
obtained from n=4 mice per genotype.  
Plasma amino acid analysis in humans 
Patient blood samples were collected under fasting conditions. Blood samples were 
collected on Guthrie cards and analyzed by LC-MS/MS and flow injection analysis-
tandem mass spectrometry (FIA-MS/MS) (Novarino et al. 2012). Plasma amino acid 
values reported in Table S5 are the result of a single blood amino acid test. Similarly, 
previous investigation didn’t reveal serum amino acid levels abnormalities. 
 
Brain amino acid analysis in mice  
Adult mice were euthanized by cervical dislocation, decapitated and the left hemisphere 
of the brain was collected, weighed and immediately homogenized in 1 ml of ice-cold 
radio immunoprecipitation assay (RIPA) buffer (50mM Tris-HCl, pH=7.4, 1% NP-40, 0.5% 
Na-deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EDTA – all from Sigma-Aldrich) in the 
presence of cOmplete Protease Inhibitor Cocktail (Complete, Roche). The tissue was 
disrupted using a glass homogenizer, transferred into a collecting tube, and left on ice for 
1 hour. The homogenate was centrifuged for 40 minutes at 100,000 X g at 4°C in a 
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SW41Ti rotor in a Beckman Optima XPN-80 ultracentrifuge (Beckman Coulter), the 
supernatant was collected and deproteinized by the addition of an equal volume of a 
solution of 8% (wt/vol) 5-sulfosalicylic acid (Sigma-Aldrich) and stored at -70°C until 
assayed for amino acid concentrations. At the time of the assay, the samples were 
thawed, mixed, centrifuged for 30 min at 5,000 X g at 4°C to remove the precipitated 
protein and assessed by HPLC (performed at Archimedlife GmbH). Four to eight animals 
per genotype/per time point (E14.5, P2 and P40) were employed for determination of 
brain amino acid levels. HPLC analysis was performed blinded to genotype. Brain amino 
acid samples were tested in duplicate in 2 to 3 independent experiments except for the 
E14.5 for which all the samples were measured in duplicate but collected and measured 
at the same day.  
 
  
RNA-sequencing 
Adult mice were euthanized under anesthesia and the brains were quickly dissected on 
ice. The cerebellum was used for RNA extraction by using 700 µL Trizol (Thermo Fisher 
Scientific) for homogenization and 140 µL chloroform (Sigma-Aldrich), followed by 
centrifugation at 12000g for 15 minutes at 4°C. The upper aqueous phase was 
transferred to a new tube and 1.5 volumes of 100% ethanol were added. Total RNA was 
extracted by using the RNA Clean&Concentrator-5 prep Kit (Zymo Research). RQ1 
RNase-Free DNase (Promega) treatment was also applied as described in the kit 
instructions manual. RNA sample quality was checked by using the NanoDrop 
spectrophotometer (Thermo Fisher Scientific) and the Bioanalyzer 2100 with the RNA 
6000 Nano kit (Agilent). Then 1.5 µg total RNA was used to generate cDNA libraries by 
following the manufacturer’s instructions in the SENSE mRNA-Seq Library Prep Kit V2 
(Lexogen). Quality check of the generated libraries was assessed by using the 
Bioanalyzer 2100 with the High Sensitivity DNA Analysis Kit (Agilent). Libraries were 
sequenced on Illumina HiSeq 2500 instrument. 
 
Western blot  
Adult mice were euthanized under anesthesia, the brain was dissected and homogenized 
in ice-cold RIPA buffer (50mM Tris-HCl, pH=7.4, 1% NP-40, 0.5% Na-deoxycholate, 
0.1% SDS, 150 mM NaCl, 2 mM EDTA – all from Sigma-Aldrich) supplemented with 
cOmplete Protease Inhibitor Cocktail (Complete, Roche) and/or with phosphatase 
inhibitor cocktail 3 (Sigma Aldrich). After 1 hour of incubation on ice, the lysates were 
centrifuged at 4°C at 14.000g for 15 minutes. The protein concentration of the 
supernatant was measured using the BioRad protein assay method (BioRad). For the 
Western blot, 30-50 μg proteins were mixed with Laemmli buffer 6x (375 mM Tris 
pH=6.8, 12%SDS, 60% glycerol, 600 mM DTT, 0.06% bromphenol blue – all fro Sigma-
Aldrich), heated to 95°C and then separated on 6-15% SDS-PAGE gels in running buffer 
(3.03 g Tris base, 14.1 g glycine, 1 g SDS –Sigma-Aldrich, 1 L MilliQ water). Proteins 
were transferred to a nitrocellulose membrane using a transfer buffer (3.03 g Tris base, 
14.1 g glycine, 1 L MilliQ water) for 2 hours at 4°C in a Bio-Rad Micro Cell Western 
blotting apparatus (300 mA constant intensity). The membranes were blocked for 1 hour 
with 5% milk in 1x TBS with 1% Tween (TBST) and incubated with primary antibody 
overnight at 4°C. After 4x10 min washes with TBST, the membranes were incubated with 
the secondary antibody for 1 hour at room temperature. Horseradish peroxidase coupled 
anti-IgG antibody was detected using an enhanced chemiluminescence substrate: Pierce 
ECL kit/Super Signal West Pico kit/Super Signal West Femto Maximum Sensitivity 
Substrate (Thermo Fisher Scientific). The following primary antibodies were used: rabbit 
anti-4E-BP1 (1:1000, Cell Signaling, 9644); rabbit anti-phospho-4E-BP1(1:1000, Cell 
Signaling, 2855); rabbit anti-eIF4E (1:1000, Cell Signaling, 2067); rabbit anti-phospho-
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eIF4E (1:1000, Cell Signaling, 9741); rabbit anti-eIF2 alpha (1:1000, Cell Signaling, 
9722); rabbit anti-phospho-eIF2 alpha (1:1000, Cell Signaling, 3398); rabbit anti-S6K 
(1:1000, Cell Signaling, 2708); rabbit anti-phspho-S6K (1:1000, Cell Signaling, 9234); 
rabbit anti-VGAT (1:200, Millipore, AB5062P); mouse anti-Tubulin beta 3 (1:1000, 
BioLegend, MMS-435P). Secondary antibodies: donkey anti-rabbit HRP (1:1000, Thermo 
Scientific, A16035); goat anti-mouse HRP (1:1000, Thermo Scientific, 31432). Each 
western blot was repeated at least in 2 independent experiments.  
Polysome profiling 
Adult mice were euthanized by cortical dislocation, dissected and the brains were 
removed. Cortices were separated and lysed in Lysis Buffer (20 mM HEPES pH 7.4, 150 
mM KCl, 5 mM MgCl2, 0,5 mM DTT, 100 µg/mL cycloheximide- Sigma-Aldrich, Roche 
Complete Protease Inhibitors (EDTA-free), 40 U/mL RNAsin - Promega, 20 U/mL 
Superasin – Thermo Fischer Scientific) using a dounce. Lysates were centrifuged for 10 
min at 2000 x g at 4°C and the resulting supernatants were supplemented with NP-40 
and Triton X-100 (both to 1%) and incubated on ice for 5 min. After centrifugation for 10 
min at 20000 x g at 4°C the debris-free supernatants were flash-frozen and stored at -
80°C until further use. Thawed supernatants were loaded onto 14 × 95 mm Polyclear 
centrifuge tubes (Seton) containing 17.5–50% sucrose gradients (in Gradient Buffer 
containing 20 mM Tris-HCl pH 7.4, 5 mM MgCl2, 150 mM NaCl, 1 mM DTT, 100 µg/mL 
cycloheximide); the sucrose gradients were generated using the Gradient Master 108 
programmable gradient pourer (Biocomp) and were centrifuged for 2.5 h at 35,000 r.p.m. 
in a SW40Ti rotor in a Beckman L7 ultracentrifuge (Beckman Coulter). After 
centrifugation gradients were fractionated and measured for RNA content using a Piston 
Gradient Fractionator (Biocomp) attached to a UV monitor (BioRad). Data represents 
mean ± SEM obtained from n=9 KO and 10 WT mice from N=2 independent 
experiments.   
 
Immunohistochemistry 
Adult mice were anesthetized by intraperitoneal injection (i.p.) of Ketamin 100mg/kg, 
Xylazine 10mg/kg and Acepromazin 3mg/kg as a mixture in one syringe. Unconscious 
state of the mouse was verified by pinching the hind limb (interdigital reflex). The 
diaphragm was opened from the abdominal side to expose the heart. A small incision 
was made in the right atrium and a butterfly needle was placed in the left ventricle to 
infuse phosphate buffered saline (PBS – Sigma-Aldrich) solution (25 mM Phosphate 
Buffer (PB), 0.9% NaCl) at 7 ml/min for 2 minutes using a perfusion pump. Afterwards the 
PBS was exchanged with a fixative solution consisting of 4% Paraformaldehyde (PFA- 
Sigma-Aldrich) + 0.05% Glutaraldehyde (Sigma-Aldrich) solution in 0.1M PB (5-10 
minutes). The brains were removed and post-fixed overnight in 4% PFA at 4°C. Next, 
brains were cryoprotected in 30% sucrose solution at 4°C for one day and embedded in 
Optimum Cutting Temperature (O.C.T., Tissue Tek) or removed from the sucrose and 
kept on dry ice and sliced. Free-floating 20 µm sections were cut using either a Microm 
HM560 cryostat (Thermo Fisher Scientific) or a sliding VT 1200S vibratome (Leica 
Microsystems). Cryostat sliced sections were used for stainings that required antigen 
retrieval (e.g. SLC7A5 staining) whereas the vibratome sliced sections were used for 
non-antigen retrieval staining and were collected in PBS. Slices were washed twice with 
PBS (10 min) at room temperature and then antigen retrieval was performed for 20 min at 
98°C in Target Retrieval Solution (Dako) pH=6 in an electric pot. Samples were cooled to 
room temperature and then washed again twice with PBS (10 min). The sections were 
permeabilized in 0.5% Triton-X 100 in PBS for 30 minutes and then blocked for 40 min in 
5% normal goat serum (Sigma-Aldrich) in 0.5% Triton-X 100 in PBS at room temperature. 
Sections were then incubated overnight with primary antibody at 4°C. The sections were 
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washed (3x10 min) with 0.01% Triton-X 100 in PBS and incubated with secondary 
antibody for 1 hour at room temperature in a dark place. Sections were incubated with 
DAPI (10 min) and then washed (3x10 min) with 0.01% Triton-X 100 in PBS and 
mounted onto glass slides with Mowiol (Sigma-Aldrich). Fluorescent signal was detected 
using a LSM 700 inverted confocal microscope (Zeiss). The following primary antibodies 
were used: rabbit anti-SLC7A5 (1:200, received from Prof. Kanai (Matsuo et al., 2000)); 
rat anti-MECA32 (1:600, Novus Biologicals, NB100-77668); rabbit anti-Parvalbumin 
(1:500, Abcam, ab11427); rat anti-Ctip2 (1:400, Abcam, ab18465); rabbit anti-Cux1 
(1:400, Santa Cruz, sc13024); rabbit anti-Somatostatin (1:1000, Penlabs, T-4103); rabbit 
anti-Calretinin (1:4500, Swant, 7697); rabbit anti-VGAT (1:200, Millipore, AB5062P); 
rabbit anti-Neuroligin 2 (1:500, Synaptic System, 129203). The secondary antibodies 
used were: donkey anti-rabbit (1:1000, Alexa Fluor 488, Life Technologies, A-21206); 
goat anti-rat (1:1000, Alexa Fluor 647, Life Technologies, A-21247). 
Immunohistochemistry experiments were repeated in at least 3 independent 
experiments. 
 
Nissl staining  
Adult mice were anesthetized and perfused with PFA 4% as described in the 
immunohistochemistry section. The brains were removed and post-fixed for 2 hours in 
4% PFA at 4°C. Next, brains were transferred to 70% ethanol overnight at 4°C. The next 
day the ethanol was replaced with fresh 70% ethanol for another hour at room 
temperature, followed by 90% ethanol for 3 hours at room temperature and eventually 
100% ethanol overnight at room temperature. On the following day brains were placed in 
a 1:1 mix of 100% ethanol : paraffin solution (ethanol is added from time to time to avoid 
complete evaporation) for 12 hours at 65°C and then moved to paraffin overnight at 65°C 
in an incubator. After this step brains were left to solidify in paraffin blocks and then 10 
µm sections were cut on a HM 355S Microtome (Thermo Fisher Scientific). Paraffin slices 
were cleared with warm Roti-Histol (Carl Roth) for 10 min and passed through absolute 
ethanol to water (96%, 90%, 70%, 50%, 30%, water) each step for 5 min. Slices were 
then kept in 1% Cresyl Violet acetate (Thermo Fisher Scientific) solution for 4 min, 
followed by destaining solution (100 ml ethanol with 2 ml 100% acetic acid) for 5-10 sec, 
absolute ethanol for 30 sec and final absolute ethanol for 1 min. At the end slices were 
cleared with Roti-Histol (10 min) and mounted with DPX (Sigma-Aldrich). Images were 
acquired using the BX53 upright light microscope with an attached DP70 digital camera 
(Olympus) and processed with Photoshop CS5.1 (Adobe Systems). Nissl staining 
observation was repeated with 3 mice per genotype at two different developmental 
stages. 
 
Electrophysiology 
Littermates of the same sex but different genotypes were randomly used to prepare brain 
slices. Acute sagittal slices (300 µm) were prepared from the cortex and from the 
cerebellum of 19 to 22 days old mice (here referred as P21). Animals were anesthetized 
by an i.p. injection of a mixture of ketamin (100 mg/kg), xylazin (10 mg/kg) and 
acepromazin (3 mg/kg), then transcardially perfused with ice-cold carbogenated solution 
containing (mM): 64 NaCl, 25 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 10 glucose, 120 
sucrose, 7 MgCl2 and 0.5 CaCl2 (all from Sigma-Aldrich, unless otherwise stated). After 
decapitation, brains were removed for sectioning in the same ice-cold cutting solution 
using a VT 1200S vibratome (Leica Microsystems). Slices were recovered in room-
temperature carbogenated regular artificial cerebrospinal fluid (mM): 125 NaCl, 2.5 KCl, 
1.25 NaH2PO4, 25 NaHCO3, 25 glucose, 1 MgCl2 and 2 CaCl2 (~320 mOsm, 7.2–
7.4 pH) for 30 min and transferred to a recording chamber (RC-41LP, Warner 
Instruments) for experiments typically between 1 and 7 h after slicing. Slices were 
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visualized under infrared-differential interference contrast (IR-DIC) using a BX-51WI 
microscope (Olympus) with a QIClickTM charge-coupled device camera (Q Imaging Inc, 
Surrey). Cerebellar Purkinje cells and cortical layer 2-3 pyramidal cells with a prominent 
apical dendrite were visually identified with a microscope equipped with IR-DIC optics 
mainly by location, shape and Clampex online membrane test parameters. 
Borosilicate glass recording microelectrodes (World Precision Instruments) were pulled 
on a P-1000 horizontal puller (Sutter Instruments) and backfilled with an internal solution 
containing (mM): 115 cessium methanesulphonate, 8 NaCl, 10 HEPES, 0.3 EGTA, 10 
Cs4BAPTA, 5 lidocaine N-ethyl chloride, 4 MgATP, 0.3 NaGTP, and 0.2% biocytin. 
Internal pH was adjusted to ~7.3 with CsOH and osmolarity adjusted to ~295 mOsm with 
sucrose. Typical internal resistance was around 1.7–3.5 MΩ. After seal rupture and 
internal equilibrium (5 min to allow proper dialysis of Cs+ internally), cells were recorded 
with series-resistance values <10 MΩ (recording traces were excluded for data analysis if 
series resistance changed by >25%). Slices were perfused with room temperature 
carbogenated regular aCSF at a rate of approximately 2 ml/min−1. Miniature excitatory 
postsynaptic currents (mEPSCs) were recorded at a holding potential of –70 mV and 
miniature inhibitory postsynaptic currents (mIPSC) at the reversal potential for mEPSC (+ 
10 mV). All voltage clamp traces were recorded in the presence of 1 μM tetrodotoxin (Bio 
Trend) with theoretical liquid junction potential not corrected for. Signals were filtered at 
0.1 kHz, digitized at 10 kHz and data acquired using a MultiClamp 700B amplifier and a 
Digidata 1550A.  
 
Electron microscopy  
21 days old mice were anesthetized by i.p. injection  of Ketamin 100mg/kg, Xylazine 
10mg/kg and Acepromazin 3mg/kg as a mixture in one syringe. Unconscious state of the 
mouse was verified by pinching the hind limb (interdigital reflex). The diaphragm was 
opened from the abdominal side to expose the heart. A small incision was made in the 
right atrium and a butterfly needle was placed in the left ventricle to infuse PBS at 7 
ml/min for 2 minutes using a perfusion pump. Afterwards the PBS was exchanged with a 
fixative solution containing 4% PFA + 5% Glutaraldehyde in 0.1M PB (5-10 minutes). The 
brains were removed and post-fixed overnight in a 0.4% PFA in 0.1M PB at 4°C. 70 µm 
sections were cut using a Vibroslicer (Leica Microsystems), collected in PB and stored in 
PB+0.02% NaN3. Sections were washed in PB and osmified with 2% osmium (Agar 
Scientific Ltd) in 0.1M PB for 45 min at room temperature. They were then washed in 
0.1M PB (10 min) and distilled water (3x10 min), and contrasted with 0.1% uranylacetate 
(Agar Scientific) in 50% ethanol solution for 30 min at room temperature in the dark. 
Samples were washed in distilled water (3x10 min) and dehydrated in ascending ethanol 
solutions (50%, 70%, 90%, 96% and 100% for 10 min each), infiltrated in propylene oxide 
(2x10 min) and embedded in Durcupan ACM (Sigma-Aldrich): propylene oxide mix 1/2 for 
1h at room temperature, 2/1 for 1h at room temperature and mere Durcupan overnight at 
room temperature. Samples were mounted on siliconized coverslips, placed on a heating 
plate for 30 min at 37°C and put in an oven for 2 days at 60°C to polymerize resin. The 
region of interest (layer 2/3 somatosensory cortex) was cut and re-embedded in a resin 
block for further slicing. 70 nm ultrathin serial sections were cut using an UC7 
ultramicrotom (Leica Microsytems), collected on formvar-coated copper-slot grids and 
examined in FE-SEM Merlin VP Compact with STEM detector (Zeiss).  
 
Behavioral studies 
All behavioral studies were carried out during the light period. Mice were habituated to 
the test room for at least 1 h before each test. In order to recover, mice were given one 
day between tests. All behavior apparatuses were cleaned between each trial with 70% 
ethanol. All behavioral tests were performed starting with the least aversive task first and 
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ending with the most aversive. Behavioral tests were performed with P55 to P65 mice 
except for the juvenile social interaction test for which P25 to P35 animals were 
employed and the ultrasonic vocalization test for which P2 to P10 pups were used. Data 
are presented as mean ± SEM. 
Open field test 
Exploratory behavior in a novel environment was assessed by a 20 min session in an 
open field chamber (45cmL x 45cmW x30cmH) made out of grey Plexiglas. The animal 
was placed in the center of the arena and then recording was started. Locomotor activity 
(distance traveled and velocity) in the center/periphery of the arena as well as rearing 
were recorded by using a video camera and analyzed using the EthoVision XT 11.5 
software (Noldus).  
Three chamber test 
Mice were tested for sociability as described previously (Moy et al., 2007). Specifically, 
the testing apparatus was a rectangular clear Plexiglas three chambers box (60cm (L) x 
40cm (W) x 20 cm (H)). The dividing walls had doorways allowing access to each 
chamber. Age and sex matched animals were used for all tests. C57BL/6J mice were 
used as stranger mice and were habituated to placement inside the wire cage. Each test 
animal was first placed into the center chamber with open access to both left and right 
chamber, each chamber containing an empty round wire cage. The wire cage (12cmH, 
11cm diameter) allows nose contact between mice but prevents fighting. After 10 min of 
habituation, during the social phase, an age-matched stranger was placed in the left 
chamber while a novel object was placed into the right chamber. The test animal was 
allowed to freely explore the social apparatus for 10 min and show whether it prefers to 
interact with the novel object or with the stranger mouse. At the end of the first 10 min, 
each mouse was tested in a second 10 min session to evaluate the preference for a 
novel stranger, which was placed inside the right wire cage. Number of nose contacts 
(<5cm proximity) with the caged mouse was calculated.  
Juvenile social interaction 
Juvenile social interactions were assessed in 25-35 days old mice in the Noldus 
PhenoTyper 3000 Observer chamber (30cm (L) x 30cm (W) x 35 cm (H)) as previously 
described (Silverman et al., 2011). Prior to the interaction session mice were individually 
housed for 1 hour. Two animals were placed simultaneously in the chamber and then 
recording started. Three types of interactions were assessed: wild-type/knockout; wild-
type/wild-type and knockout/knockout, between age and sex matched subjects. 
Interactions were tracked for 10 min using a digital camera incorporated in the 
PhenoTyper chamber. Ineractions were scored using the EthoVision XT 11.5 software 
(Noldus) and included number of nose-nose sniffing and distance between subjects.   
Walking beam test 
Fine motor coordination and balance was assessed by the beam walking assay (Carter 
et al., 2001). This test essentially examines the ability of the animals to remain upright 
and to walk on an elevated and relatively narrow beam. The beam apparatus consists of 
several 1 meter-long beams with diameters of 5 cm, 3 cm and 1 cm, resting 50 cm above 
the floor on two poles. During the test a mouse is placed on one extremity of the beam 
and a black box was placed at the end of the beam as finish point. The test took place 
over 3 consecutive days, 2 days training and 1 day testing (3 trials per day). In between 
trials mice were allowed to rest in their cages for 10 min. On the training days mice were 
allowed to cross the 5 and 3 cm beams while on the test day mice walked on the 1 cm 
beam. A nylon hammock was stretched below the beam to cushion any falls. A video 
camera was set on a tripod to record the performance. Performance on the beam was 
quantified by measuring the latency to cross the beam.  
Isolation-induced ultrasonic vocalizations (USVs) in mouse pups 
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Whistle like sounds (between 30-90 kHz) were recorded from newborn pups as 
previously described (Scattoni et al., 2009). A microphone (part of the Noldus UltraVox 
XT system) was placed inside a dark, soundproof polycarbonate box (37cm (L) x 37cm 
(W) x 57cm (H)). Neonatal pups (postnatal days 2, 4, 6, 8, 10) were separated from their 
mother and placed inside the recording chamber. USVs were recorded for 3 minutes and 
afterwards the pup was placed back with its mother until weaning time.  
Gait measurement test 
Gait was analyzed by performing the footprint test as previously described (Carter et al., 
2001). Specifically, the fore and hind paws were painted with nontoxic dyes of different 
colors and then the mouse was allowed to walk in a straight line (in a narrow corridor 
using as bait a cage at the end of the walkway) over absorbent paper. The footprint 
patterns were then analyzed for stride length, sway length and stance length.  
Marble burying test 
Stereotyped behavior was assessed by placing adult mice (60 days old) into an usual 
animal cage (30cm (L) x 20cm (W) x 20cm (H), Tecniplast) filled with 5cm deep chip 
bedding, as previously described (Deacon, 2006). Bedding was reused between sex 
matched animals. A regular pattern of glass marbles (5 rows of 4 marbles) was placed on 
the bedding and the subject was allowed to explore for 25 min. The number of buried (to 
2/3 of their depth in bedding) marbles was counted.  
Hind limb clasping test 
As previously described (Guyenet et al., 2010), mice were grasped by their tail and 
suspended. Hind limb position was observed for 10 seconds. If the hind limbs were 
retracted towards the abdomen then the mouse was marked as positive for clasping. The 
test was repeated three times. At the end of the test the mouse was placed back into its 
cage. The test was repeated three times for each animal.  
Kyphosis test 
Kyphosis is a characteristic curvature of the spine that is common in mouse models of 
certain neurological disorders (Guyenet et al., 2010). The mouse was removed form its 
cage and placed on a flat surface. While it was walking, we observed whether it was able 
to easily straighten its spine completely. If it was not the case, the mouse was marked as 
positive for kyphosis. At the end of the test the mouse was placed back into its cage. The 
test was repeated three times for each animal. 
 
Intracerebroventricular dye injection 
40 days old mice were injected s.c. with meloxicam 5 mg/kg one hour prior surgery in 
order to achieve analgesia and then anesthetized initially with isoflurane 4% and O2 0.5-
1L/min in a gas chamber. Once anesthetized (checked by toe pinching), the mouse was 
placed in a Kopf stereotaxic frame and a nose cone was placed over the nose with 
isoflurane volume turned down to 2% to maintain the anesthesia. After sterilizing the 
surgical site with betadine, a midline incision was made over the skull and a small hole 
was drilled above the left lateral ventricle. Using a Hamilton syringe, connected to the 
Kopf stereotactic frame, 10 µL of dye was delivered into the ventricle in order to check 
later on the injection site accuracy. The coordinates used relative to bregma were: 
anterioposterior (AP) = -0.5 mm, medial lateral (ML) = -1.1 mm, dorsal ventral (DV) = -3 
mm. To allow diffusion of the dye into the brain, the needle was left for 5 min at the site of 
injection. The incision was manually closed using a topical tissue adhesive (GLUture, 
World Precision Instruments). Two hours later the mouse was euthanized and the brain 
was kept overnight in 4% PFA. The next day the brain was embedded in 3% agarose 
blocks and then sliced (100 µm) using a VT 1200S vibratome (Leica Microsystems) in 
order to assess the diffusion of the dye in the entire ventricular system and to confirm the 
correct positioning of the needle in the left ventricle.   
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Serial surgical implantation of cannula and osmotic pumps 
One day before the surgery, a micro-osmotic pump (ALZET model 1007D) was filled with 
100 µL of a saline amino acid solution (isoleucine 100 mM, leucine 100 mM). The pump 
was then connected through a plastic catheter to a cannula with a 0.5 mm spacer 
attached to it (ALZET Brain Infusion Kit 3). The pump was designed to deliver the 
solution at a rate of 0.5 µL/hour for 7 days. The pump and cannula assembly was kept in 
saline overnight at 37oC. Adult mice were injected s.c. with meloxicam 5 mg/kg one hour 
prior surgery in order to achieve analgesia and then anesthetized initially with isoflurane 
4% and O2 0.5-1L/min in a gas chamber. Once anesthetized (checked by toe pinching), 
the mouse was placed in a Kopf stereotaxic frame and a nose cone was placed over the 
nose with isoflurane volume turned down to 2% to maintain the anesthesia. Eyes were 
covered with ointment in order to prevent drying out. During surgery metamizol 200mg/kg 
was administered subcutaneously (s.c.) to ensure maintenance of analgesia. After 
sterilizing the surgical site with betadine, a midline incision was made over the skull and a 
subcutaneous pocket was created on the back of the animal. The pump was then 
inserted inside the pocket and a small hole was drilled above the left lateral ventricle 
following the coordinates identified during the calibration study performed with dye 
injections and as previously described (DeVos and Miller, 2013), AP = -0.5 mm, ML = -
1.1  mm, DV = -2.5mm. The incision was manually closed using a topical tissue adhesive 
(GLUture, World Precision Instruments). The incision site was sterilized with betadine 
and an ointment was applied to keep the spot moisturized. One week later the pump was 
replaced with a 200 µL micro-osmotic pump (ALZET model 2002) filled with the same 
amino acid solution as mentioned above. The replacement procedure was done following 
the same steps as described for the 100 µL pump. The mice were singly caged until the 
time for behavioral testing (e.g. walking beam test, gait measurement, open field test). 
Behavioral tests were performed with P55 to P65 mice. At the end of the three-week 
administration, mice were euthanized and their brains were dissected for HPLC protein 
analysis. Data represent means ± SEM; n=10 (untreated) control, n=4 (treated) control, 
n=11 (untreated) mutant and n=8 (treated) mutant mice. 
 
Whole exome sequencing, homozygosity profile and variant prioritization 
DNA was extracted from peripheral blood leukocytes using salt extraction. For family 
1426 blocks of homozygosity were determined by HomozygosityMapper. Whole-Exome 
Sequencing and variant analysis was performed using solution hybrid SureSelect 
reagents (Agilent, Mountain View, CA) and sequenced on an Illumina GAIIx or 
HiSeq2000 instrument (Gnirke et al., 2009). The sequence reads were aligned to the 
human genome (hg19), genetic variants were delineated using the Genome Analysis 
ToolKit (GATK 1.1) software and SAMTools (v1.4-r985) algorithms, for both single 
nucleotide polymorphisms (SNPs) and Indels. 
Variants were prioritized using the following criteria: 
1. The variant was predicted to perturb protein function. All synonymous and 
intronic variants were excluded unless the variant was within a predicted splice site (+ or 
-2 bp from splice junction). Any variation that was predicted to alter gene expression or 
protein function was included. These included nonsynonymous variations in coding 
regions (i.e. missense) or alterations resulting in frameshifts, premature stop codons, loss 
of stop codons, coding INDELS, and splice sites (i.e. ± 2 nucleotides from an exon 
junction). 
2. The variant was rare as defined by allele frequency of less than 0.2%. Allele 
frequencies were determined by an in-house database of over 1500 Middle Eastern 
exomes, and public databases provided by The Exome Variant Server from NHLBI GO 
Exome Sequencing Project (ESP) and dbSNP135.  
3. The variant was present in a region of homozygosity as defined by 
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HomozygosityMapper  
4. The variant was highly conserved throughout evolution as determined by a number of 
conservation scores including GERP, PhastCons, and PolyPhen2. Variations with 
negative GERP scores or vertebrate PhastCons scores less than .8 were excluded. 
Typical conservation criteria for the candidate genes provided in this study were GERP > 
4 and vertebrate PhastCons > .9. 
5. The variant segregated with the disease in the family pedigree. All variants following 
the above criteria were considered for each family independent of its predicted severity 
(i.e. no variants were excluded based upon type of mutation). 
 
The remaining variants were ranked by type of mutation (indels > nonsense > missense), 
amino acid conservation across species and protein damage prediction based upon 
location of the mutation in a specialized protein domain. The variants were annotated for 
novelty and compared with dbSNP (build 132) and control samples analyzed by whole-
exome sequencing experiments performed by our human genomics groups. Variants 
were analyzed against the RefSeq gene definitions, a list that includes 18,933 specific 
genes. Where multiple isoforms gave varying results the one most likely to lead to protein 
disruption was chosen.  
 
Sanger sequencing 
Primers were designed using the Primer3 program and tested for specificity using 
ENSEMBL's BLAST software. PCR products were treated using Exonuclease I (Thermo 
Fisher Scientific) and Shrimp Alkaline Phosphatase (Affymetrix) and sequenced using the 
Big Dye terminator cycle sequencing Kit v.3.1 (Applied Biosystems) on an ABI 3100 DNA 
analyzer (Applied Biosystems). The sequence data were analyzed using Sequencher 4.9 
(Gene Codes).  
Leucine uptake assay  
Leucine uptake was performed as previously described (Sinclair et al., 2013). Briefly, 
300.000 cells were plated in a single well of 6 well plates two days before the assay. The 
day of the experiment the cells were washed twice with HBSS and incubated in HBSS 
containing [3H] leucine (Perkin Elmer) 0.5 uCi/ml alone or in the presence of 10 mM 
leucine or 3 mM BCH (Wang et al., 2011). Cells were incubated at 37°C for 1 hour. At the 
end of the incubation each well was washed twice with cold PBS and lysed with 1 mM 
NaOH for 2 hours at 37°C. Total leucine uptake was measured by liquid scintillation 
counting (Packard Tri-Carb 2100TR).   
Cloning, mutagenesis and expression of the human SLC7A5 wild-type and mutants  
The construct pH6EX3-wt SLC7A5 obtained as previously described (Galluccio et al., 
2013) and containing the SLC7A5 cDNA was used for site-directed mutagenesis. 
Specific mutants of the SLC7A5 cDNA were obtained by PCR overlap extension 
methods, as previously done for other proteins (Galluccio et al., 2015), using the primers 
in Table S4. 
 
To supply tRNA for rare codons, Rosetta(DE3)pLysS E. coli strain was transformed either 
with SLC7A5 wild type or mutant proteins (Galluccio et al., 2013) and selected on agar 
plates supplemented with ampicillin and chloramphenicol. A colony was picked and 
cultured overnight at 37 °C under rotary shaking (about 200 rpm) in selective LB broth 
and the day after was diluted 1:10 in same medium. When the culture reached the mid 
logarithmic phase of growth, 0.4 mM IPTG was added and temperature was lowered at 
28°C for 4 hours as previously described (Galluccio et al., 2013). 
 
 43 
Purification of human SLC7A5 wild-type and mutants 
Pellets from induced cell lysates were used for protein purification as previously 
described (Napolitano et al., 2015). In brief, after washing (0.1 M Tris HCl pH 8.0), pellets 
were solubilized using a 20 mM Tris/HCl pH 8.0 buffer containing 10 mM DTE, 0.8 % 
sarkosyl, 3.5 M urea, 10 % glycerol, 200 mM NaCl. Solubilized cell lysates were 
centrifuged (12,000 g, 10 min, 4 °C) and the supernatants were applied on a His Trap HP 
column (5 ml Ni Sepharose), connected to fast protein liquid chromatography (FPLC) 
ÄKTA start and equilibrated with 10 mL buffer (20 mM Tris HCl pH 8.0, 10 % glycerol, 
200 mM NaCl, 0.1 % sarkosyl, and DTE 2 mM). During purification procedure, column 
was washed with 10 mL of washing buffer (20 mM Tris HCl pH 8, 10 % glycerol, 200 mM 
NaCl, 0.1 % n-Dodecyl β-D-maltoside and 3 mM DTE – all from Sigma-Aldrich). Then, 
proteins were eluted by an isocratic step of 400 mM imidazole in the above described 
buffer. Fractions 6-8 (2.5 mL) were pooled and desalted on a PD-10 column using a 
desalting buffer (20 mM Tris HCl pH 8.0, 10% glycerol, 0.05% n-Dodecyl β-D-maltoside 
and 10 mM DTE). 
 
Reconstitution of human SLC7A5 wild type and mutants in proteoliposomes 
The purified SLC7A5 wild type and mutants were reconstituted by removing the 
detergent using the batch-wise method as previously described (Napolitano et al., 2015). 
In brief, 4 μg of protein (in 200 μL) were mixed to 100 μL of 10% C12E8, 100 μL of 10% 
egg yolk phospholipids (w/v) in the form of sonicated liposomes prepared as previously 
described (Scalise et al., 2014), 20 mM Tris HCl pH 7.5, 10 mM DTE, 100 mM K-
gluconate and 10 mM l-His, except where differently indicated, in a final volume of 700 
μL. The mixture was incubated with 0.5 g Amberlite XAD-4 resin under rotatory stirring 
(1200 rev/min) at room temperature (25 °C) for 90 min (Napolitano et al., 2015).  
Transport measurements 
After reconstitution uptake and efflux experiments were conducted at 25°C. For uptake 
experiments, 600 μL of proteoliposomes were passed through a Sephadex G-75 column 
(0.7 cm diameter × 15 cm height) pre-equilibrated with 20 mM Tris HCl pH 7.5 and 
sucrose at appropriate concentrations to balance the internal osmolarity. Transport was 
started by adding 5 μM [3H]His to the proteoliposomes. For efflux experiments, 
proteoliposomes containing 2 mM His, were preloaded with 5 μM [3H]His at high specific 
radioactivity (1μCi/ml) for 30 min by transporter-mediated exchange equilibration. 
Proteoliposomes were then passed through Sephadex G-75, as above described, to 
remove external compounds. Efflux was started by adding, or not, 1 mM of 
unradiolabelled His. In both uptake and efflux assays, transport was stopped by adding a 
mix of 10 μM 2-amino-2-norbornanecarboxylic acid (BCH) and 1 μM HgCl2 at the desired 
time interval. In control samples, the inhibitor was added at time zero. At the end of the 
transport assay, each sample of proteoliposomes (100 μL) was passed through a 
Sephadex G-75 column (0.6 cm diameter × 8 cm height) to separate the external from 
the internal radioactivity. Proteoliposomes were eluted with 1 mL 50 mM NaCl and 
collected in 4 mL of scintillation mixture, vortexed and counted. The experimental values 
were corrected by subtracting each sample inhibited at time zero. For kinetic 
measurements, the initial rate of transport was measured by stopping the reaction after 
10 min, i.e., within the initial linear range of [3H]His uptake.  
 
Ultracentrifugation of proteoliposomes 
SLC7A5 WT and SLC7A5-A246V reconstituted proteoliposomes were passed through 
Sephadex G-75 column and 500 µl were ultracentrifuged (110,000 g, 1 h 30 min, 4°C). 
Pellets were washed with 20 mM Tris HCl pH 8.0 and ultracentrifuged again. Pellets were 
solubilized with 3% SDS and subjected to SDS-PAGE 12% run and western blot 
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analysis. SLC7A5 WT and mutants were immuno-detected using anti-SLC7A5 antibody 
1:2000, upon overnight incubation at 4°C. The reaction was detected by Electro Chemi 
Luminescence (ECL) assay after incubation with secondary antibody anti-rabbit 1:5000. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS  
Statistical values including the exact n, statistical significance, definition of center, and 
dispersion and precision measures are reported in the Figure Legends. Student’s t-test 
was mostly used and one-way ANOVA was used where appropriate (i.e., multiple 
comparisons). Data are shown as means ± SEM and were judged to be statistically 
significant when p < 0.05. In each graph circles/dots represent individual values. All data 
sets were analyzed using Shapiro–Wilk test for normality. 
 
Amino acid data  
Amino acid levels were normalized on the initial protein concentration and are displayed 
as fold change (log2 transformed) to levels in controls. Data analysis was done in 
GraphPad Prism 7 and student’s t-test was used to test for significance. Mouse plasma 
amino acid values reported in Table S1 represent mean ± SEM obtained from n=4 mice 
per genotype. Brain amino acid values represent mean ± SEM obtained from 4 to 8 mice 
per genotype per time point from at least 2 independent experiments. 
 
RNA-sequencing 
Demultiplexed raw reads were trimmed before alignment as suggested by the library 
preparation kit, i.e. the first 9 bases of each read were removed using the FASTX toolkit. 
Trimmed reads were aligned to the mouse genome using STAR version 2.5.4 (genome: 
GrCm38, gene annotation: Gencode release M8). Reads that didn’t align uniquely were 
discarded. Read counts per gene were also calculated using STAR (option -quantMode 
GeneCounts). Differential expression analysis was performed in R 3.2.4 employing the 
Bioconductor package DESeq2 version 1.10.1 using an FDR threshold of 0.05, a local fit 
for the dispersion estimation and default parameters otherwise. Gene Ontology 
enrichment analysis was done using the Bioconductor package GOstats version 2.36.0 
with a p-value cutoff of 0.001 and conditional testing enabled. GO enrichment results 
were visualized using a custom script. RNA sequencing was performed employing n=3 
mice per genotype.  
 
Protein data  
Western blot  
Western blot images were acquired by Peqlab Fusion SL Advance Multi Imaging system 
(VWR) and quantified using ImageJ software. Protein levels are displayed as fold 
change. Student’s t-test was used to test for significance (GraphPad Prism 7). Data 
represent mean ± SEM obtained from two to five mice per genotype typically from at least 
2 independent experiments. 
 
Polysome profiling  
Analysis was performed blinded to genotype. For quantitative analysis of individual 
elements (e.g. 80S monosomes, polysomes, etc) from the polysome profiles, all traces 
were first exported to Microsoft Excel and adjusted as necessary to ensure matching x/y-
axis scales. Traces were then exported to Photoshop CS5.1 and ImageJ for processing, 
baseline setting, cropping and pixel counting. The pixel counts were used for determining 
polysome/monosome values and for plot generation. Student’s t-test was used for the 
statistical analysis (GraphPad Prism 7). Data represents mean ± SEM obtained from n=9 
KO and 10 WT mice from two independent experiments. All data sets were analyzed 
using Shapiro–Wilk test for normality. 
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Immunohistochemistry  
Fluorescent signal was detected using a LSM 700 inverted confocal microscope (Zeiss) 
and images were processed with Photoshop CS5.1 (Adobe Systems). Control and 
mutant samples were always treated equally and in parallel (e.g. if brightness or contrast 
were adjusted identical changes were applied for all the samples). For each antibody, 
immunostainings were repeated in multiple animals (typically 3 per genotype) obtaining 
comparable results. We counted all parvalbumin, somatostatin and calretinin 
interneurons as well as VGAT and NLGN2 puncta intensity on coronal sections at 
different positions. Neurons/puncta quantified in a given animal were added together. 
Means and SEM were calculated across animals, and student’s t-test was done across 
animals (n=3 animals per genotype).   
 
Neuronal data  
Analysis was performed blinded to genotype using pCLAMP 10.4 software (Axon 
Instruments/Molecular Devices). Statistical analyses were performed using Origin 
Software (Origin Inc), Clampfit and R. All data sets were analyzed using Shapiro–Wilk 
test for normality. Data sets with normal distributions were analyzed for significance using 
one-way ANOVA measures with Bonferroni post-hoc test, using *P < 0.05, **P < 0.005. 
Data sets with non-normal distributions were analyzed using the 2-tailed Mann-Whitney U 
test using *P < 0.05. Exact P values are presented in each figure. Cumulative 
distributions were analyzed using the Kolmogorov-Smirnov test. Data represent means ± 
SEM, ncells/nanimals/genotype: 14/7/Tie2Cre;Slc7a5fl/+ and 13/5/Tie2Cre;Slc7a5fl/fl (mEPSC); 
16/7/Tie2Cre;Slc7a5fl/+ and 18/5/Tie2Cre;Slc7a5fl/fl (mIPSC).   
Electron microscopy  
Analysis was performed blinded to the genotype. ATLAS 5 array tomography (Zeiss) was 
used for image acquisition and 3D reconstruction of sample data. Image J software was 
used for quantification of the symmetric synapse vesicular pool and measurement of the 
presynaptic terminal area. All data sets were analyzed using Shapiro–Wilk test for 
normality and met the criteria for normality. GraphPad Prism 7 was used for statistical 
analysis applying student’s t-test. Data represent means ± SEM; nsynapses/genotype: 
27/control and 22/mutant.    
Behavior  
Quantification of the different behavioral parameters was done using the EthoVison XT 
11.5 (Noldus) and UltraVox XT software (Noldus). Data met the criteria for normal 
distribution (Shapiro–Wilk test), thus student’s t test was used for statistical analysis for 
most of the behavioral data. For the three chamber test one-way ANOVA with Fisher’s 
post-hoc test was applied and for the juvenile social interaction test one-way ANOVA with 
Bonferroni's post-hoc test was used (GraphPad Prism 7). Number of animals employed 
for each test is reported in the figure legend describing each experiments and range from 
n=6 to n= 13 animal per genotype. At least two independent cohorts were examined for 
each test.  
 
Transport measurement data 
For the efflux experiments, the [3H]His efflux was calculated by subtracting radioactivity 
values at each time point from that present in the proteoliposomes at time zero. 
Uptake data were fitted in a first-order rate equation to obtain rate constants and in 
Michaelis–Menten or Linewever-Burk equations. Efflux data were fitted in a single 
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exponential decay equation. The Grafit software (version 5.0.13) was used for data 
fitting. To measure the specific activity of SLC7A5 WT and mutants, protein quantity was 
estimated from Coomassie blue stained SDS-PAGE gels by using the Chemidoc imaging 
system equipped with Quantity One software (Bio-Rad) as previously described 
(Galluccio et al., 2012). Data represent mean ± SD obtained from n= 4 to 5 independent 
experiments. 
For the fibroblast leucine uptake assay the results of were obtained from at least 3 
independent experiments (5 for family 1426 and 3 for family 1465) each one employing 
fibroblasts from at least 1 unaffected and 1 affected individual of the same family. For 
family 1426, given the very invasive procedure, we obtained skin biopsies only from 2 
affected (patient 1426-6 and 1426-19) and 2 unaffected individuals (1426-1 and 1426-2). 
The graph in Figure 6E represents the average of the transport values obtained for either 
both the affected or the unaffected subjects in all the performed experiments. As 
deducible from the small error bar we didn’t notice strong variability among individuals of 
the same family. 
 
DATA AND SOFTWARE AVAILABILITY  
 
Data resources  
The data reported in this paper is deposited into GEO under the accession numbers: 
GSE87808 (RNA-seq Slc7a5) and GSE39447 (microarrays Bckdk), and into NCBI 
Sequence Read Archive: SRS351252 (whole exome sequencing).   
 
ADDITIONAL RESOURCES 
The URLs for data presented herein are as follows: 
Online Mendelian Inheritance in Man (OMIM): http://www.omim.org  
SeattleSeq Annotation: http://gvs.gs.washington.edu/   
Genome browser: http://www.genome.ucsc.edu/  
HPLC analysis: http://www.archimedlife.com/de/   
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Table S1. Serum amino acid profile, Related to 
Figure 1 
 ! !Amino acid Slc7a5fl/+;Tie2Cre Slc7a5fl/fl;Tie2Cre 
4-AMINOBUTYRIC ACID 0,71 +/- 0,12 0,45 +/- 0,25 
4-HYDROXYPROLINE 15,96 +/- 2,79 11,77 +/- 5,94 
ALANINE 837,42 +/- 161,14 648,79 +/- 91,05 
ARGININE 172,17 +/- 84,57 137,68 +/- 16,67 
ASPARAGINE 37,98 +/- 11,83 31,15 +/- 7,23 
ASPARTIC ACID 14,57 +/- 5,79 9,65 +/- 1,83 
CITRULLINE 104,9 +/- 13,13 97,42 +/- 10,97 
CYSTINE 5,15 +/- 1,81 2,12 +/- 0,55 
GLUTAMIC ACID 125,52 +/- 36,6 124,86 +/- 39,36 
GLUTAMIN 1072,97 +/- 191,3 1063,33 +/- 194,95 
GLYCINE 440,03 +/- 55,91 402,34 +/- 47,3 
HISTIDINE 84,98 +/- 9,92 82,67 +/- 7,19 
ISOLEUCINE 81,69 +/- 19,26 85,29 +/- 9,76 
LEUCINE 170,93 +/- 40,01 173,66 +/- 14,88 
LYSINE 387,39 +/- 81,18 346,79 +/- 42,39 
METHIONINE 76,58 +/- 17,9 63,54 +/- 8,17 
ORNITHINE 105,02 +/- 33,1 68,11 +/- 8,79 
PHENYLALANINE 104,88 +/- 25,57 98,44 +/- 7,53 
PROLINE 155,95 +/- 67,36 96,76 +/- 20,59 
SERINE 201,36 +/- 36,26 199,09 +/- 29,73 
THREONINE 194,8 +/- 56,9 175,1 +/- 28,61 
THYROSINE 100,41 +/- 26,39 84,72 +/- 18,65 
TRYPTOPHAN 118,39 +/- 33,66 116,48 +/- 23,42 
VALINE 305,33 +/- 77,64 266,69 +/- 24,86 
   !
Table S2. Segregating, rare variants discovered in the affected individuals using 
w
hole-exom
e sequencing, R
elated to Figure 5
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Relevant brain amino acids were measured by HPLC. Levels  
measured in the mutant mice were normalized on control 
level. 
Table S3. Brain amino acid levels after leucine 
and isoleucine i.c.v. administration, Related to 
Figure 7  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Relevant brain amino acids were measured by HPLC. Levels measured in the mutant mice  
were normalized on control levels. 
 Slc7a5fl/fl Tie2Cre;Slc7a5fl/fl 
GLUTAMIN 1 ± 0.51 1.25 ± 0.20 
CITRULLINE 1 ± 0.21 1.07 ± 0.15 
SERINE 1 ± 0.39 2.66 ± 0.25 ** 
4-
HYDROXYPROLINE 
1 ± 0.55 0.96 ± 0.13 
GLYCINE 1 ± 0.36 2.07 ± 0.18 ** 
THREONINE 1 ± 0.53 2.25 ± 0.14 ** 
GABA 1 ± 0.32 0.88 ± 0.08  
PROLINE 1 ± 0.22 1.58 ± 0.11 ** 
HISTIDINE 1 ± 0.55 4.51 ± 0.60 ** 
VALINE 1 ± 0.32 0.94 ± 0.11 
TRYPTOPHAN 1 ± 0.37 2.25 ± 0.43 ** 
PHENYLALANINE 1 ± 0.31 2.01 ± 0.15 ** 
LEUCINE 1 ± 0.23 0.96 ± 0.13 
ISOLEUCINE 1 ± 0.25 1.09 ± 0.17 
THYROSINE 1 ± 0.33 2.17 ± 0.18 ** 
Table S4. Mutagenesis primer sequences, 
Related to STAR Methods  !
Primer 
name  
Primer sequence  
A246G 
Forward 
GTGGGGAACATTGTGCTGGGCTTATACAGCGGCCTCTTTGC 
A246V 
Forward 
GTGGGGAACATTGTGCTGGTGTTATACAGCGGCCTCTTTGC 
P375L 
Forward 
CTCCTCACCCCCGTGCTGTCCCTCGTGTTCACG 
A246G 
Reverse 
GCAAAGAGGCCGCTGTATAAGCCCAGCACAATGTTCCCCAC 
A246V 
Reverse 
GCAAAGAGGCCGCTGTATAACACCAGCACAATGTTCCCCAC 
P375L 
Reverse 
CGTGAACACGAGGGACAGCACGGGGGTGAGGAG ! !!
 Table S5. Plasma amino acid levels from members of 
family 1426, Related to STAR Methods (Human 
subjects) 
 
Amino Acid 1426-12 (U) 1426-6 (A) 
Normal range 
(2-18 years old) 
Glycine 226.1 215.9 127-341 
Ornithine 22.7 15.1 10-163 
Arginine 0.9 0.5 10-140 
Citrulline 10.2 11.7 1-46 
Alanine 601.1 579.3 152-547 
Serine 189.4 202.2 69-187 
Valine 219.1 164.0 74-321 
Threonine 48.7 50.4 35-226 
Leucine+Isoleucine 189.3 148.8 N.A. 
Methionine 20.1 18.6 7-47 
Histidine 71.5 46.0 41-125 
Phenylalanine 71.9 58.4 N.A. 
Tyrosine 57.6 51.0 24-115 
Aspartate 7.7 23.0 1-24 
Glutamate 59.7 131.1 5-150 
 
Plasma amino acids were quantified on bloodspot cards by FIA-MS or LC-MS/MS at the 
Mayo Clinic (Novarino et al. 2012). U, unaffected; A, affected. Values are expressed in 
nmol/ml.      
 
 
Table S1. Serum amino acid profile, Related to 
Figure 1 
 ! !Amino acid Slc7a5fl/+;Tie2Cre Slc7a5fl/fl;Tie2Cre 
4-AMINOBUTYRIC ACID 0,71 +/- 0,12 0,45 +/- 0,25 
4-HYDROXYPROLINE 15,96 +/- 2,79 11,77 +/- 5,94 
ALANINE 837,42 +/- 161,14 648,79 +/- 91,05 
ARGININE 172,17 +/- 84,57 137,68 +/- 16,67 
ASPARAGINE 37,98 +/- 11,83 31,15 +/- 7,23 
ASPARTIC ACID 14,57 +/- 5,79 9,65 +/- 1,83 
CITRULLINE 104,9 +/- 13,13 97,42 +/- 10,97 
CYSTINE 5,15 +/- 1,81 2,12 +/- 0,55 
GLUTAMIC ACID 125,52 +/- 36,6 124,86 +/- 39,36 
GLUTAMIN 1072,97 +/- 191,3 1063,33 +/- 194,95 
GLYCINE 440,03 +/- 55,91 402,34 +/- 47,3 
HISTIDINE 84,98 +/- 9,92 82,67 +/- 7,19 
ISOLEUCINE 81,69 +/- 19,26 85,29 +/- 9,76 
LEUCINE 170,93 +/- 40,01 173,66 +/- 14,88 
LYSINE 387,39 +/- 81,18 346,79 +/- 42,39 
METHIONINE 76,58 +/- 17,9 63,54 +/- 8,17 
ORNITHINE 105,02 +/- 33,1 68,11 +/- 8,79 
PHENYLALANINE 104,88 +/- 25,57 98,44 +/- 7,53 
PROLINE 155,95 +/- 67,36 96,76 +/- 20,59 
SERINE 201,36 +/- 36,26 199,09 +/- 29,73 
THREONINE 194,8 +/- 56,9 175,1 +/- 28,61 
THYROSINE 100,41 +/- 26,39 84,72 +/- 18,65 
TRYPTOPHAN 118,39 +/- 33,66 116,48 +/- 23,42 
VALINE 305,33 +/- 77,64 266,69 +/- 24,86 
   !
Table S2. Segregating, rare variants discovered in the affected individuals using 
w
hole-exom
e sequencing, R
elated to Figure 5
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Relevant brain amino acids were measured by HPLC. Levels  
measured in the mutant mice were normalized on control 
level. 
Table S3. Brain amino acid levels after leucine 
and isoleucine i.c.v. administration, Related to 
Figure 7  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Relevant brain amino acids were measured by HPLC. Levels measured in the mutant mice  
were normalized on control levels. 
 Slc7a5fl/fl Tie2Cre;Slc7a5fl/fl 
GLUTAMIN 1 ± 0.51 1.25 ± 0.20 
CITRULLINE 1 ± 0.21 1.07 ± 0.15 
SERINE 1 ± 0.39 2.66 ± 0.25 ** 
4-
HYDROXYPROLINE 
1 ± 0.55 0.96 ± 0.13 
GLYCINE 1 ± 0.36 2.07 ± 0.18 ** 
THREONINE 1 ± 0.53 2.25 ± 0.14 ** 
GABA 1 ± 0.32 0.88 ± 0.08  
PROLINE 1 ± 0.22 1.58 ± 0.11 ** 
HISTIDINE 1 ± 0.55 4.51 ± 0.60 ** 
VALINE 1 ± 0.32 0.94 ± 0.11 
TRYPTOPHAN 1 ± 0.37 2.25 ± 0.43 ** 
PHENYLALANINE 1 ± 0.31 2.01 ± 0.15 ** 
LEUCINE 1 ± 0.23 0.96 ± 0.13 
ISOLEUCINE 1 ± 0.25 1.09 ± 0.17 
THYROSINE 1 ± 0.33 2.17 ± 0.18 ** 
Table S4. Mutagenesis primer sequences, 
Related to STAR Methods  !
Primer 
name  
Primer sequence  
A246G 
Forward 
GTGGGGAACATTGTGCTGGGCTTATACAGCGGCCTCTTTGC 
A246V 
Forward 
GTGGGGAACATTGTGCTGGTGTTATACAGCGGCCTCTTTGC 
P375L 
Forward 
CTCCTCACCCCCGTGCTGTCCCTCGTGTTCACG 
A246G 
Reverse 
GCAAAGAGGCCGCTGTATAAGCCCAGCACAATGTTCCCCAC 
A246V 
Reverse 
GCAAAGAGGCCGCTGTATAACACCAGCACAATGTTCCCCAC 
P375L 
Reverse 
CGTGAACACGAGGGACAGCACGGGGGTGAGGAG ! !!
 Table S5. Plasma amino acid levels from members of 
family 1426, Related to STAR Methods (Human 
subjects) 
 
Amino Acid 1426-12 (U) 1426-6 (A) 
Normal range 
(2-18 years old) 
Glycine 226.1 215.9 127-341 
Ornithine 22.7 15.1 10-163 
Arginine 0.9 0.5 10-140 
Citrulline 10.2 11.7 1-46 
Alanine 601.1 579.3 152-547 
Serine 189.4 202.2 69-187 
Valine 219.1 164.0 74-321 
Threonine 48.7 50.4 35-226 
Leucine+Isoleucine 189.3 148.8 N.A. 
Methionine 20.1 18.6 7-47 
Histidine 71.5 46.0 41-125 
Phenylalanine 71.9 58.4 N.A. 
Tyrosine 57.6 51.0 24-115 
Aspartate 7.7 23.0 1-24 
Glutamate 59.7 131.1 5-150 
 
Plasma amino acids were quantified on bloodspot cards by FIA-MS or LC-MS/MS at the 
Mayo Clinic (Novarino et al. 2012). U, unaffected; A, affected. Values are expressed in 
nmol/ml.      
 
 
